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Abstract 
The intent of this dissertation is to make a contribution to the field of pharmacovigilance. 
Pharmacovigilance, also known as post-marketing drug surveillance, is the process of 
continued monitoring for adverse drug reactions (ADRs) after drugs are released into the 
market. An ADR is a harmful or unpleasant reaction related to the use of a medical product. 
ADRs were reported to be between the fourth and sixth leading cause of death in the United 
States in 1994, accounting for 3-7% of medical hospital admissions. On account of the 
practice of pharmacovigilance, Vioxx (Rofecoxib) and Avandia (Rosiglitazone) are 
examples of high profile drugs that were suspended from the American or European 
market. 
To prevent these effects on human health, pre-marketing clinical trials are designed to test 
drug safety and efficacy. Although clinical trials are extensive and last multiple years, rare 
ADRs may not be detected, and others may occur on account of idiosyncratic 
characteristics of individuals excluded from the evaluated sample.  
To aid the pharmacovigilance process, automated methods for the identiﬁcation of strongly 
correlated drug/ADR pairs from data sources such as adverse event reporting systems, or 
Electronic Health Records (EHRs), have been developed. These methods however are 
generally statistical in nature, and do not draw upon the large volumes of knowledge 
embedded in the biomedical literature.  
iv 
In this dissertation I investigate the ability of scalable Literature Based Discovery (LBD) 
methods to identify side eﬀects of pharmaceutical agents in a computationally automated 
manner. LBD methods can provide evidence from the literature to support the plausibility 
of a drug/ADR association, thereby assisting human review to validate the signal, which is 
an essential component of pharmacovigilance. The hypothesis underlying this work is that 
by combining signals mined from EHR data with biomedical domain knowledge, the 
accuracy of side effects detection may be improved. This also addresses the lack of 
causality assessment in existing statistical methods in pharmacovigilance practice.  
My theoretical contribution is that by conducting automated abductive reasoning and by 
estimating the strength of generated explanatory hypotheses the plausibility of a drug/ADR 
signal can be assessed. I adapt and extend the original abductive reasoning process as 
defined by Peirce in 19th century by stating that the strength of the explanations found for 
an observation is a measure for its plausibility, rather than taking an observation as given.  
Practical contributions to pharmacovigilance and informatics include the development of 
methods to leverage the knowledge from biomedical literature, the detection of signals 
from the EHR data and the subsequent evaluation using supporting evidence from the 
literature on a large scale in an automated way, and the development of an improved 
drug/ADR reference set. My contributions are not restricted to pharmacovigilance and as 
such constitute a contribution to the field of informatics in general. 
I demonstrate that my work has extended the state of the art in EHR-based 
pharmacovigilance and contribute new ideas that pave the way for further studies with the 
potential to further enhance the field of pharmacovigilance and drug safety.  
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Chapter 1: Introduction 
1.1 Significance of Pharmacovigilance 
An adverse drug reaction (ADR) is an “appreciably harmful or unpleasant reaction, 
resulting from an intervention related to the use of a medical product” (Edwards & 
Aronson, 2000). ADRs contribute to substantial morbidity, health care visits and hospital 
admissions (Baker et al., 2004; Chan, Nicklason, & Vial, 2001; Hamilton, Briceland, & 
Andritz, 1998; Lazarou, Pomeranz, & Corey, 1998; Pirmohamed et al., 2004). For 
example, ADRs were reported to be between the fourth and sixth leading cause of death in 
the United States in 1994 (Lazarou et al., 1998), accounting for 3-7% of medical hospital 
admissions (Baker et al., 2004; Hamilton et al., 1998) and a substantial number of health 
care visits (Bourgeois, Mandl, Valim, & Shannon, 2009). A recent observational study 
conducted in two emergency departments shows that 8.9% of emergency patients had a 
probable ADR (Capuano et al., 2004). Overall, they have a considerable negative impact 
and place an enormous burden on both health and healthcare system (Pirmohamed et al., 
2004; Rodríguez-Monguió, Otero, & Rovira, 2003) and consequently constitute a notable 
public health problem (Capuano et al., 2004). 
To prevent these harmful effects on human health, pre-marketing clinical trials are 
designed to test drug safety and efficacy. Phase III clinical trials have been estimated to 
cost 86.3 million US dollars and last 30.5 months on average (DiMasi, Hansen, & 
Grabowski, 2003). Nonetheless, rare ADRs may not be detected due to the limited duration 
2 
and sample size of such trials, and others may occur on account of idiosyncratic 
characteristics of individuals excluded from the evaluated sample. The continued 
monitoring for ADRs after drugs are released into the market, referred to as 
pharmacovigilance (also known as post-marketing drug surveillance), is therefore an 
important tool to monitor and improve drug safety (Mann & Andrews, 2007). For example, 
on account of the practice of pharmacovigilance, Vioxx (Rofecoxib) was withdrawn 
voluntarily worldwide in 2004 because of the finding of increased risk of heart attack 
(Merck, 2004). Similarly, Avandia (Rosiglitazone) was suspended from the European 
market in 2010 by the European Medicines Agency (EMA) (FDA, 2011; Ye, 2011).  
 
1.2 Challenges in pharmacovigilance and suggested solutions 
Over the last decade, the World Health Organization (WHO), the Food and Drug 
Administration (FDA), EMA and others instituted spontaneous reporting systems (SRSs) 
for the systematic collection of ADR reports (Rawlins, 1988a). Drug safety data obtained 
from SRSs have been analyzed using quantitative data mining procedures to retrieve 
strongly associated drug/ADR pairs (Puijenbroek, Diemont, & van Grootheest, 2003; 
Rawlins, 1988a, 1988b). These highlighted associations are subsequently reviewed and 
scrutinized by domain experts. These are essential parts of a pharmacovigilance system, 
which are referred to as drug/ADR signal detection and evaluation (A. Bate et al., 1998; A. 
Bate, Lindquist, Edwards, & Orre, 2002; Bates, Lindquist M., Orre R., Edwards I., & 
Meyboom R., 2002).  
There are two major problems with these processes. First, research suggests data collected 
by SRS are limited by long time latency, incorrect or incomplete clinical information, 
3 
underreporting and reporting bias (Rawlins, 1988a, 1988b; Hasford, Goettler, Munter, & 
Müller-Oerlinghausen, 2002; Alvarez-Requejo et al., 1998). Second, it has been argued 
that causality assessment is lacking in pharmacovigilance practice (Anderson & Borlak, 
2011). The WHO defines causality assessment as the evaluation of the likelihood that a 
medicine caused the observed adverse event (WHO-Uppsala Monitoring Centre, 2013). 
The lack of this evaluation is due to the expense and time involved in manual review by 
domain experts. In practice resources are too limited for the large number of signals 
produced by SRSs.  
A potential workaround to the resource limitations is to use information from other sources 
to supplement SRSs. Drug intake and symptoms are documented by clinicians in EHR data, 
although the rate of false positives is expected to be high because the number of possible 
adverse events is small compared to the number of desired treatment outcomes. After 
filtering known drug indications a causality assessment of statistically significant signals 
is necessary to identify possible side effects. Potential and known mechanisms of action 
are described in detail in the biomedical literature. It is therefore possible to leverage 
domain knowledge from biomedical literature to make statements about the plausibility of 
drug/ADR connections. The hypothesis underlying this work is that by combining signals 
mined from EHR data with biomedical domain knowledge, the accuracy of side effect 
detection may be improved. 
I evaluate this hypothesis in a series of experiments, First, I apply disproportionality 
measures and Chi-square test to analyze drug-event co-occurrence data derived from EHR 
to find statistically significant drug/ADR associations and evaluate the performance of 
these statistical algorithms. For the statistically significant drug/ADR associations, I apply 
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scalable methods of literature-based discovery (LBD) (Hristovski, Friedman, Rindflesch, 
& Peterlin, 2006; Kostoff, Briggs, Solka, & Rushenberg, 2008; Swanson, 1986b) 
leveraging methods of distributional semantics (Cohen, Schvaneveldt, & Widdows, 2010; 
Cohen, Widdows, Schvaneveldt, Davies, & Rindflesch, 2012; Widdows & Cohen, 2010) 
to evaluate the plausibility of their connections. I do this by utilizing knowledge from the 
published literature to automatically generate explanatory hypotheses which collectively 
contribute to a plausibility score and a subsequent reranking according to their plausibility. 
This also alleviates the problem of an overwhelming amount of associations for manual 
expert review. 
During the course of this research, it came to my attention that there is no agreed-upon gold 
standard in pharmacovigilance (Tatonetti, Ye, Daneshjou, & Altman, 2012). This may 
affect the performance evaluation because of the existing false drug/ADR associations in 
the reference data. So a reference set was developed and used for additional performance 
evaluation in this study. 
To reiterate, the unifying hypothesis that is tested in the dissertation is that drug/ADR 
signal detection from EHRs can be improved by integrating knowledge from the 
biomedical literature.  
 
1.3 Dissertation structure 
This dissertation is structured as follows. In Chapter 2, I review literature related to the 
field of and recent research in pharmacovigilance as well as LBD methods and 
distributional semantics. In the following chapters I perform a series of experiments to 
evaluate my hypotheses. In Chapter 3, I describe the first experiment, in which statistical 
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mining algorithms are used to find statistically correlated drug/ADR associations from 
EHR data. In Chapter 4, I build LBD based distributional semantic models to identify 
plausible ADRs using knowledge extracted from the literature. In Chapter 5, a drug/ADR 
association reference set is built as a subset of a dataset containing known side effects. The 
subset contains only those associations that are confirmed to be statistically significant 
using data from an SRS. In Chapter 6, I evaluate the effects of plausibility based reranking 
on the precision of the statistically significant drug/ADR associations detected in EHR 
data. In this experiment, two reference sets are utilized and the performance against these 
sets is compared. The dissertation concludes with describing its significance and 
contributions to the field of pharmacovigilance, informatics and public health.  
1.4 Key contributions 
The purpose of this dissertation is to automatically identify drug/ADR associations that are 
most likely causal among those signals detected from EHR with statistical methods by 
integrating domain knowledge from the biomedical literature that is related to side effects.  
 A surprising drug/ADR signal (surprise observation) is detected from an EHR 
system.  
 There is a genuine doubt about this observation (doubt).  
 To resolve the doubt, an inquiry is initiated (inquiry) by searching the literature to 
support plausible connections between the drug and the ADR.  
 Supporting plausibility evidence is subsequently utilized as sufficient explanation 
(explanation) to relieve the doubt about the surprising observation.  
My theoretical contribution is that by conducting automated abductive reasoning 
(Josephson & Josephson, 1996; Locke, Golden-Biddle, & Feldman, 2008; Peirce, 1955; 
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Schvaneveldt & Cohen, 2010) and by estimating the strength of generated explanatory 
hypotheses the plausibility of an observation (in this work, a drug/ADR signal) can be 
assessed. This means that I adapt the original abductive reasoning process by stating that 
the strength of the explanations found for an observation is a measure for its plausibility. 
A low plausibility likely implies that an observation is a false positive and should be 
considered for rejection. A high measure of plausibility on the contrary supports the 
validity of the observation.  
This differs from the original line of thought by introducing a measure to assess plausibility 
rather than taking the observation as a given fact.  
The practical contributions to pharmacovigilance and informatics are as follows: 
 The development of methods to leverage knowledge from the literature as a 
means to assess the plausibility of observations from EHR data.  
 The detection of signals from EHR data and the subsequent evaluation using 
supporting evidence from literature in pharmacovigilance on a large scale in an 
automated way.  
 The development of a drug/ADR reference set based on both an established side 
effects repository and a high volume drug/ADR data set from an SRS. 
 The methods and procedures of integrating formal knowledge can be generalized 
and applied to other domains, such as outbreak detection, for which a timely 
identification of plausibility for signals is essential. This is not restricted to 
pharmacovigilance and constitutes a contribution to the field of informatics in 
general.  
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Chapter 2: Literature Review 
2.1 Pharmacovigilance: post-marketing drug surveillance 
2.1.1 Pharmacovigilance definition and significance 
Vioxx (Rofecoxib) was withdrawn voluntarily from market by Merck in 2004, after it was 
found that the use of this agent increased the risk of myocardial infarction (Merck, 2004). 
Graham et al (Graham et al., 2005) estimated that between 88,000 and 140,000 excess 
serious coronary heart diseases might have been caused by rofecoxib in the US since it was 
launched in 1999. Avandia (Rosiglitazone) was suspended from the European market in 
2010 (Blind, Dunder, Graeff, & Abadie, 2011; EMA, 2010; Ye, 2011) on account of an 
increased risk of cardiovascular complications. These high-profile examples illustrate that 
pharmacovigilance is very important to supplement existing drug safety profiles because 
clinical drug trials cannot be large or long enough to identify all problems related to a new 
drug (Rawlins, 1988a). Additionally, subjects are pre-selected by eligibility criteria and 
therefore may not fully represent the patient population after the drugs are put to market 
(Anderson & Borlak, 2011). Besides, some patient may have idiosyncratic drug reactions 
which cannot be explained by the pharmacological effect of the drug (Knowles, Uetrecht, 
& Shear, 2000). Consequently, it is highly unlikely that instances of all possible ADRs will 
be detected during pre-marketing clinical trials.  
To address this problem, health departments and organizations (such as the World Health 
Organization (WHO), United States Food and Drug Administration (FDA), and European 
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Medicines Agency (EMA)) encourage physicians, other health care professionals, and 
patients to report voluntarily about any observed ADRs. In addition to voluntarily 
reporting, pharmaceutical companies are mandatory required to report serious adverse 
events (Ahmad, 2003). These bodies have Spontaneous Reporting Systems (SRS) to enable 
the efficient submission of reports electronically (Kessler et al., 1993; Wysowski & Swartz, 
2005).  
Since 1969, the FDA Adverse Event Reporting System (FAERS), which provides the 
means for clinicians to report suspected adverse events electronically, collected more than 
7 million case reports (Fine, 2013) and the number of ADR reports submitted to the FDA 
continues to grow (Figure 2-1). More than 75 drug products have been removed from the 
market due to safety problems from 1969 to 2002 (Wysowski & Swartz, 2005). The facts 
emphasize the importance of post-marketing drug monitoring, known as 
pharmacovigilance – “the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other drug-related problem after 
drugs are on market” (WHO, 2010). Pharmacovigilance is designed to detect any rare or 
long-term adverse effects over a very large population and a long period of time.  
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Figure 2-1: Number of adverse event reports reported to FDA categorized by reporter 
(top left), by patient outcome (top right), by geographic sources (bottom left) and by 
types of reports (bottom right) from 2001 to 2011 
 
2.1.2 Pharmacovigilance workflow in related health departments 
In general, the pharmacovigilance process proceeds as follows (Andrew Bate, 2003; 
Edwards, 1992; Lindquist et al., 1999):  
(1) Reported drug-related problems are collected in SRSs nationally or internationally;  
(2) Quantitative data mining procedures are used to analyze these data and retrieve 
relatively strongly correlated drug/ADR pairs (drug/ADR associations);  
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(3) These highlighted associations are then reviewed and evaluated by domain experts 
making up an expert clinical review panel; and  
(4) Associations considered to be of clinical interest are then annotated as “signals”.  
Specifically, signal is defined as “reported information on a possible causal relationship 
between an adverse event and a drug, the relationship being unknown or incompletely 
documented previously” (Edwards & Biriell, 1994; van Puijenbroek et al., 2002). Overall, 
the pharmacovigilance process in WHO (Andrew Bate, 2003), FDA (Fine, 2013; Gould, 
2005) and EU-ADR initiative (P. Lopes et al., 2013) includes two components -- a 
statistical component (quantitative signal detection, steps (1) and (2)) and a qualitative 
component (expert clinical review, steps (3) and (4)) (Andrew Bate, 2003). Figure 2-2 
demonstrates the specific pharmacovigilance workflow in FDA.  
2.1.3 Pharmacovigilance data sources 
Through pharmacovigilance, international and national health institutions gather large 
amount of data mainly from SRS for further analysis. In addition to case reports, 
specialized networks and active surveillance data are also considered as data sources for 
detecting safety signals, even though they are in experimental phrases (FDA Science Board 
Subcommittee, 2011). Specialized networks, such as the Drug Induced Liver Injury 
Network (DILIN) (Hoofnagle, 2004), focus on collecting side effects data concerning 
specific organ targets, patterns of ADRs or patient populations. Active surveillance efforts, 
such as Sentinel Network (Platt et al., 2009; Platt, Madre, Reynolds, & Tilson, 2008) and 
Observational Medical Outcomes Partnership (OMOP) (Stang et al., 2010), utilize existing 
systems for the purpose of drug monitoring (U.S. Food and Drug Administration, 2008). 
Examples of potentially useful systems include EHRs, pharmacoepidemiological databases 
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(Johansson, Wallander, de Abajo, & Rodriguez, 2010), health insurance claims databases 
(Brown et al., 2007, 2009), and so forth. the Observational Medical Outcomes Partnership 
(OMOP) uses EHR and other data sources to identify ADR signals and the preliminary 
results demonstrate that active surveillance from EHR systems can complement current 
pharmacovigilance practice, but also that performance varies by data source, drug and 
outcomes of interest (FDA Science Board Subcommittee, 2011).  
 
 
Figure 2-2: FDA pharmacovigilance process – adapted from (Fine, 2013; Gould, 2005) 
 
With the opportunity presented by EHRs’ broader availability, researchers have also used 
EHR data for drug safety research and  have attempted to demonstrate that EHR data are a 
relevant and significant data source for pharmacovigilance (Collins, 2011; Wang, 
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Hripcsak, Markatou, & Friedman, 2009). These authors argue that EHR data can 
compensate for some of the deficiencies of SRS, such as under-reporting, misclassification, 
a long lag time between observation and reporting, reporting bias and the provision of 
incomplete background clinical information (Rawlins, 1988a, 1988b).  
 
2.2 Pharmacovigilance methodology 
2.2.1 Statistical data mining from pharmacovigilance database 
Statistical algorithms are routinely applied to SRSs (A. Bate et al., 1998; W. DuMouchel 
& Pregibon, 2001; W DuMouchel, 1999; Lindquist et al., 1999; Lindquist, Stahl, Bate, 
Edwards, & Meyboom, 2000; Noren, Bate, Orre, & Edwards, 2006) to measure the strength 
of reported drug-event associations. Quantitative data mining procedures are measuring 
“disproportionality”. Reporting disproportionality is defined as a statistically significant 
higher reporting frequency of particular drug/ADR associations compared with marginal 
distributions of drugs and ADRs as a background in the reporting database (Shibata & 
Hauben, 2011). These disproportionality measures quantify how often a drug and a 
possible event co-occur compared to the background reporting occurrence across all other 
drugs and events using an independence model (Manfred Hauben, Madigan, Gerrits, 
Walsh, & Van Puijenbroek, 2005). The reporting of the event related to other drugs in the 
database is used as a proxy for the background occurrence of the event (Poluzzi, Raschi, 
Piccinni, & De Ponti, 2012). To put it in another way, different disproportionality measures 
quantify the extent to which a given event is frequently reported with a given drug by 
estimating the observed-to-expected co-occurrence ratio. Those drug-event pairs that are 
significantly different from background reporting occurrence may reflect credible signals 
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that need further investigation. However, reported ADRs do not necessarily accurately 
reflect the usage of drugs and the incidence of ADRs in the population (Poluzzi et al., 
2012), the significant pairs may represent reporting tendencies (Manfred Hauben & Reich, 
2005). Commonly used disproportionality measures include the proportional reporting 
ratio (PRR) (Evans, Waller, & Davis, 2001), the reporting odds ratio (ROR) (Puijenbroek 
et al., 2003), Bayesian confidence propagation neural network (BCPNN, information 
component (IC) is the statistical score) (A. Bate et al., 1998; Lindquist et al., 1999, 2000; 
Noren et al., 2006), multi-item gamma Poisson Shrinker (MGPS, empiric Bayes geometric 
mean (EBGM) is the statistical score) (W. DuMouchel & Pregibon, 2001; W DuMouchel, 
1999), and others (Table 2-1). Different comparison references are used to estimate the 
expected ADR occurrences in frequency probability based measures. The observed for all 
drugs and the observed for all other drugs are used to estimate the expected occurrence of 
the ADR for PRR and ROR respectively (Poluzzi et al., 2012). With Bayesian methods, if 
a drug and an ADR is independent, then their joint probability to the product of the 
individual probabilities will equal to 1 (Poluzzi et al., 2012). This inference hypothesis is 
used to calculate and interoperate observed-to-expected co-occurrence ratio. Roux et al. 
(E. Roux et al., 2003) evaluated these statistical models on simulated datasets (constructed 
by SRS modeling for arbitrary selected 150 drugs and 100 side effects) by comparing the 
percentage of false positive signals among given drug-event combinations (Emmanuel 
Roux, Thiessard, Fourrier, Begaud, & Tubert-Bitter, 2005). The false positive rates varied 
from 1.1% to 53.4%; and EBGM, IC and Chi-square models seemed to have better 
performances (Emmanuel Roux et al., 2005). Puijenbroek et al. (van Puijenbroek et al., 
2002) also evaluated different measures and found out that sensitivity was high with respect 
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to the reference measure when a combination of point- and precision estimates was used. 
For example, in the PRR measure, the PRR is the point estimate; and its lower limit of 95% 
Confidence Interval (CI) is the precision estimate.  
 
 
 
 Table 2-1: Quantitative data mining procedures used as disproportionality measures in SRS (Balakin & Ekins, 2009; M. Hauben & 
Bate, 2009; Manfred Hauben et al., 2005; Emmanuel Roux et al., 2005; van Puijenbroek et al., 2002) 
 Reports with the suspected event j Reports without the suspected event j 
Reports with the drug i of interest a(=nij) b 
Reports with all other drugs c d 
 
Measure of Association and Data 
source 
Formula 
Measure of importance Probabilistic 
Interpretation 
Frequentist Approaches 
Proportional Reporting Ratio (PRR) 
(Evans et al., 2001) 
UK Yellow Card database, 
Medicines Control Agency (MCA) 
 
  
Reporting Odds Ratio 
(ROR) (Puijenbroek et al., 2003) 
Netherlands Pharmacovigilance 
Centre Lareb 
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     Table 2-1:  Continued 
Measure of Association and Data 
source 
Formula 
Measure of importance Probabilistic 
Interpretation 
Bayesian Approaches 
Relative Risk (RR) 
 
WHO BCPNN and FDA MGPS 
 
 
 
 
 
 
A: ADR; D: Drug; BCPNN: Bayesian Confidence Propagation Neural Network; MGPS: Multi-item gamma Poisson Shrinker 
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2.2.2 Taxonomic reasoning 
In addition to the use of quantitative techniques, ontology-based reasoning in combination 
with quantitative data mining methods has been shown to be able to improve signal 
detection from SRSs (J. S. Almenoff et al., 2007; Bousquet, Henegar, Louėt, Degoulet, & 
Jaulent, 2005; Bousquet, Trombert, Kumar, & Rodrigues, 2008; Henegar, Bousquet, Lillo-
Le Louët, Degoulet, & Jaulent, 2006; Mera, Beach, Powell, & Pattishall, 2010; Nadkarni, 
2010). Different methods of ontological reasoning were conceived. Two examples, coined 
terminological reasoning by subsumption and approximate matching (Bousquet et al., 
2005), are summarized in the following.  
In a terminological hierarchy, when multiple subclasses are connected to one superclasses, 
it is said that the superclass subsumes all of the subclasses. Reasoning by subsumption then 
means that a given class and all of its subsumed classes are considered to be one entity. 
The new entity then constitutes all of the signals of the individual classes into one, 
increasing its number of occurrence. In SRSs, ADRs are usually coded using the Medical 
Dictionary for Regulatory Activities (MedDRA) terminology, and MedDRA’s hierarchy 
was used to facilitate terminological reasoning by subsumption. 
In approximate matching, a new concept is built as the disjunction of all sets of possible 
characteristics. For example, Hepatitis is defined as “((hyperbilirubinemia AND ALAT 
increased) OR (ASAT increased AND cholestasis) OR (jaundice AND cytolysis))” 
(Bousquet et al., 2005). This is another way to group cases to increase the number of 
occurrences of identifiable drug/ADR associations. 
These and other approaches and combinations of both approaches have been shown to 
improve signal detection by exploiting ontological properties with statistical data mining 
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methods (J. S. Almenoff et al., 2007; Bousquet et al., 2005, 2008; Mera et al., 2010; 
Nadkarni, 2010).  
 
2.3 Predicting drug side effect relations 
2.3.1 Machine learning algorithms 
Other researchers have attempted to predict which drugs cause which side effects using 
machine learning approaches with structured knowledge concerning the drugs and ADRs 
as features. Liu et al. applied five supervised machine learning (ML) algorithms with drug 
features drawn from PubChem (chemical substructures), DrugBank (drug target, 
transporters, and enzymes), KEGG (pathway) and SIDER itself (drug indication and side 
effects). A ML classifier was built for each SIDER ADR. The classifiers were then 
evaluated on 832 SIDER drugs (for which DrugBank IDs could be found) using five-fold 
cross-validation. Of the algorithms evaluated, the support vector machine (SVM) algorithm 
performed best with an AUC of 0.9054 on the SIDER dataset as a whole (Liu, Wu, et al., 
2012).  
In other work (Huang, Wu, & Chen, 2011), the features were selected from drug-target 
information from DrugBank and drug non-target protein information from an expanded 
protein-protein interaction (PPI) network derived from gene ontology (GO) annotations. A 
SVM classifier was built for each ADR and cross-validated on a known side effect resource 
(SIDER, version 1).  
In related work, decision tree models were derived for specific end organs using features 
derived from the chemical structure of the agents in the SIDER set. The accuracies of 
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decision trees for allergic, renal, central nervous system (CNS) and hepatic ADRs ranged 
from 78.9% to 90.2% (Hammann, Gutmann, Vogt, Helma, & Drewe, 2010). 
In addition to supervised ML algorithms, unsupervised learning using topic models has 
also been used to analyze drug labels and group drugs by topics that are associated with 
the same side effects (Bisgin, Liu, Fang, Xu, & Tong, 2011).  
2.3.2 Regression and correlation analysis 
Pauwels and colleagues applied sparse canonical correlation analysis (SCCA) utilizing the 
chemical substructure of drugs to predict side effects (Pauwels, Stoven, & Yamanishi, 
2011). Features representing drugs’ chemical substructures were extracted from PubChem. 
Side effects were extracted from SIDER. Canonical correlation analysis (CCA) is a way of 
measuring the linear relationship between two multidimensional variables and customized 
to analyze the relationship between the group of chemical substructure and the group of 
side effects and to find what chemical substructure can represent what side effect. Highly 
correlated sets of chemical substructures and side effects were retrieved, and predictive 
scores associating substructures to side effects were calculated. SCCA is a variant of 
canonical correlation analysis that aims to minimize the size of the set of features utilized 
so as to facilitate explanation. The AUC for SCCA is 0.8932 for predicting side effects.  
In another study, logistic regression was used to predict ADRs using as features chemical 
substances from PubChem and BioAssay (a database of bioactivity screens of chemical 
substances). Performance was evaluated for side effects related to specific organ systems, 
and was best for immune system disorders (AUC=0.92) and blood and lymphatic system 
disorders (AUC=0.79) (Pouliot, Chiang, & Butte, 2011).  
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2.3.3 Mining literature to predict drug/ADR associations 
Currently, systematic literature review is utilized as an in-depth investigation to provide 
scientific evidence to confirm a specific drug/ADR relationship or support regulatory 
decisions (for example, drug withdrawal) in the pharmacovigilance process (Arnaiz et al., 
2001; Y. K. Loke, Kwok, & Singh, 2011; Yoon K Loke, Price, & Herxheimer, 2007; P. 
Lopes et al., 2013; Marie et al., 2008; Olivier & Montastruc, 2006). However, evidence in 
the biomedical literature (e.g. case reports, clinical trials) may appear before an ADR is 
recognized. This implies that analyzing the literature to predict drug/ADR associations may 
complement current drug safety methods (disproportionality measures of SRS). This aspect 
of pharmacovigilance has been explored in a few studies only (Alomar, Hourani, & 
Sulaiman, 2008; Deftereos, Andronis, Friedla, Persidis, & Persidis, 2011; Shetty & Dalal, 
2011).  
There are two major investigative perspectives. One perspective involves using the 
literature as a data source for ADR case reports, and then applying statistical models to 
mine the drug/ADR associations (Alomar et al., 2008; Shetty & Dalal, 2011). Shetty et al. 
(Shetty & Dalal, 2011) retrieved literature about side effects by searching PubMed using 
NLM’s Medical Subject Headings (MeSH) index, and then filtering irrelevant articles (for 
example articles discuss only treatments) using a Lasso-based document relevance 
classifier (Genkin, Lewis, & Madigan, 2007). With the contingency table built from 
drug/ADR occurrence across all relevant citations, a disproportionality analysis was 
applied to find statistically significant drug/ADR associations. This model discovered 54% 
of all detected FDA warnings from labeling and also confirmed the association between 
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rofecoxib and heart disease with literature before 2002 while rofecoxib was recalled in 
2004.  
The second perspective is based on the paradigm of literature-based discovery (LBD), and 
involves processing the literature to uncover indirect relationships between drugs and 
ADRs. Using LBD for pharmacovigilance has not been attempted until recently Hristovski 
et al. (Hristovski et al., 2006) model LBD discovery patterns to analyze semantic 
predications and find therapeutic relations for drugs and a disease. To date, LBD-inspired 
pharmacovigilance research has concerned providing justification for a connection 
between a drug and an ADR, or investigating possible mechanisms to explain an observed 
side effect using the literature (Ahlers, Hristovski, Kilicoglu, & Rindflesch, 2007; 
Hristovski, Burgun-Parenthoine, Avillach, & Rindflesch, 2012a). However, this approach 
has not yet been evaluated as a means to predict side effects on a large scale. I will elaborate 
further on this aspect in Section 2.7.1.  
2.3.4 Statistical data mining from EHR for signal detection 
Using EHR data for pharmacovigilance is an active research area (Wang et al., 2009). 
Disproportionality measures applied to SRSs have been applied to EHR data also (Zorych, 
Madigan, Ryan, & Bate, 2011; Liu, McPeek Hinz, et al., 2012). However, these algorithms 
were designed for reporting systems to evaluate whether a given event is disproportionally 
“reported” with a given drug. As side effects may not be explicitly reported in the EHR, 
the applicability of disproportionality measures to EHR data must still be evaluated 
(Zorych et al., 2011). Zorych et al. (Zorych et al., 2011) hypothesize that the observed co-
occurrence of a drug and an event can be regarded as though they were reported as a 
spontaneous reporting case, to produce drug-event contingency tables. Using this 
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approach, existing disproportionality algorithms were applied to both real world and 
simulated EHR data. Results show that the disproportionality algorithms can find 
legitimate drug/ADR associations; they also produce a large number of false positive 
associations. Liu et al. (Liu, McPeek Hinz, et al., 2012) assessed disproportionality 
measures on drug-laboratory test ADR associations derived from EHR data. This study 
further demonstrated that disproportionality measures can be applied to analyze EHR data 
for pharmacovigilance. Of note, these EHR data (Zorych et al., 2011; Liu, McPeek Hinz, 
et al., 2012) were structured.  
However, most clinical information also includes unstructured narratives, which contain 
valuable patient data. Several researchers (Cao, Hripcsak, & Markatou, 2007; Cao, 
Markatou, Melton, Chiang, & Hripcsak, 2005; Wang et al., 2009) have investigated 
measuring co-occurrence within the narrative section of the EHR as a means to detect 
possible drug/ADR associations. This is accomplished by calculating above-chance 
occurrences of drug and problem pairs in the clinical notes, where each note represents a 
clinical encounter. Associations among entities are estimated using statistical methods 
(Chi-Square statistics) based on their co-occurrence statistics in the clinical notes. Co-
occurrence statistics (Christopher D. Manning & Hinrich Schütze, 1999) have been 
successfully applied in the computational linguistics domain, for example, for the purpose 
of word sense disambiguation (Yarowsky, 1995), automatic generation of semantic 
lexicons (Roark & Charniak, 1998) and synonym mining (Turney, 2001). In addition to 
word-level co-occurrence statistics, concept-level co-occurrence has also been used to 
discover associations between concepts (Cao et al., 2005). If a drug causes an ADR, then 
this drug and this related problem are more likely to appear together than random 
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combinations of drugs and adverse events in clinical notes (Cao et al., 2005). It has been 
demonstrated that co-occurrence statistics can be derived from unstructured EHR data to 
detect possible side effects (Wang et al., 2009).  
 
2.4 Pharmacovigilance challenges from my perspective 
The above review of the literature highlights two major challenges: inefficient and 
incomplete SRS data and the lack of computer-assisted causality assessment in 
pharmacovigilance practice. As discussed in section 2.1.3, EHR may compensate for the 
limitations of SRSs and provide the opportunity for active surveillance. As argued in 
(Anderson & Borlak, 2011), there is a lack of causality assessment in pharmacovigilance 
practice. While expert clinical review is designed to verify potential ADRs, it is a human-
intensive and time-consuming process. The available human resources are inadequate to 
review the large amount of noisy signals detected in SRS and EHR data, creating a 
bottleneck in the pharmacovigilance process. More research is needed to develop methods 
to automate, or assist with, the knowledge-intensive task of expert clinical review. In the 
section that follows, I will discuss emerging methodologies that I propose adapting in order 
to address these limitations: EHR data can be used as an alternative data source for 
pharmacovigilance and scalable LBD methods based on distributional semantics can be 
utilized to assist signal evaluation. 
 
2.5 Signal detection from EHR 
An EHR system presents the possibility of a real-time, continuous approach to drug 
surveillance (Brown et al., 2007; Trifirò et al., 2009; Wang et al., 2009). It has been 
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estimated that Vioxx would have been withdrawn in just 3 months instead of 5 years if the 
EHR data of 100 million patients had been available for drug monitoring (McClellan, 2007; 
Pray, Robinson, & Translation, 2007; Trifirò et al., 2009; Wagner et al., 2006). In addition 
to review the statistical mining from EHR (Section 2.3.4), I continue to review the recent 
proposed framework using EHR for pharmacovigilance from a pilot study (Wang et al., 
2009).  
Wang et al. (Wang et al., 2009) proposed a pharmacovigilance framework utilizing an EHR 
system. The basic procedure is: (1) Drug-relevant data (both structured and unstructured) 
are extracted from the EHR. A Natural Language Processing (NLP) tool is used to parse 
free-text clinical notes because unstructured data may include richer patient information; 
(2) The drug relevant data are coded and mapped to a standard terminology for further 
analysis; (3) Drug and related event pairs are selected by filtering indication relationships 
and excluding incorrect temporal order of events (i.e. side effect before drug 
administration); (4) Selected drug-event pairs are analyzed using statistical data mining 
algorithm (Chi-square statistics) to obtain a ranked ADR list for all respective drugs based 
on the strength of the statistics; (5) For each drug’s ranked ADR list, an empirical threshold 
of significance level is adjusted by volume tests using the P-value plot (Schweder & 
Spjøtvoll, 1982; Cao et al., 2005, 2007; Wang et al., 2009) to determine possible signals 
for each drug.  
Essentially, there are two major tasks required to use EHR data for pharmacovigilance. The 
first task is to process and clean EHR data to get drug-event combinations and retrieve 
these combinations’ co-occurrence data using informatics tools. Second is to conduct 
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statistical analysis to analyze these co-occurrence data of drugs and events to detect the 
significant drug/ADR pairs.  
ADR signals have relatively low incidence in comparison with background information in 
the EHR (for example, therapeutic relationships are more common) because EHRs are not 
designed for ADR monitoring. This leads to noise, which means the application of basic 
statistical methods alone will detect many false signals. Thus estimating a threshold to find 
stronger associations maybe difficult (Cao et al., 2007; Wang et al., 2009). However, 
pharmacovigilance from EHR can provide good signal candidates for further investigation.  
 
2.6 Expert clinical review and causality assessment in pharmacovigilance 
2.6.1 Expert clinical review in pharmacovigilance 
Since the beginning of pharmacovigilance practice (mid 1960s), expert clinical review has 
been viewed as essential to assess causality during the signal evaluation process 
(Agbabiaka, Savović, & Ernst, 2008; Andrews & Moore, 2014; Andrew Bate, 2003). 
Detected signals are reviewed by one or more experts who are often specialists, with 
expertise related to the ADR concerned (Andrews & Moore, 2014). This is referred to as 
expert judgement or global introspection -- an expert expresses a judgement about possible 
drug causation after having taken into account all the available and relevant information 
on the considered case (Arimone et al., 2007). Expert judgment assessments are generally 
expressed in terms of a qualitative probability scale (Andrews & Moore, 2014). For 
example, the WHO causality categories are ‘Certain’, ‘Probable’, ‘Possible’, ‘Unlikely’, 
‘Conditional/unclassified’, and ‘Unassessable/unclassifiable’(Meyboom, Hekster, 
Egberts, Gribnau, & Edwards, 1997). During the assessment, specific structured 
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approaches have been used to guide the experts from which perspective to evaluate the 
possible ADR. For instance, the Swedish regulatory agency (Wiholm, 1984) recommends 
the experts to assess possible ADRs from the following aspects: (1) the temporal sequence, 
(2) previous information on the drug, (3) dose relationship, (4) response pattern to drug, 
(5) rechallenge, (6) alternative aetiological candidates, and (7) concomitant drugs. 
2.6.2 Assessment of causality 
To address the assessment of causality, general principles exist that can be applied to 
evaluate the causality of potential ADRs (Shakir & Layton, 2002). The theoretical basis 
for these principles was proposed by Sir Austin Bradford-Hill in 1965 (Hill, 1965). 
Bradford-Hill, an English epidemiologist and statistician, was the first to demonstrate that 
cigarette smoking contributes toward lung cancer using what are now referred to as the 
“Bradford-Hill criteria” (Richard Doll, 1994). The Bradford-Hill criteria provide 
viewpoints from which to evaluate evidence indicative of causality and have been widely 
used in pharmacoepidemiology. These criteria are named ‘strength’, ‘consistency’, 
‘specificity’, ‘temporality’, ‘biological gradient’ (referring to dose-response relationships), 
‘plausibility’, ‘coherence’, ‘experimental evidence’, and ‘analogy’ (Hill, 1965; Kleinberg 
& Hripcsak, 2011; Ward, 2009). Since then, the criteria have been widely used in 
epidemiology and may be applied to assess the causality of drug/ADR relationships 
(Anderson & Borlak, 2011; Perrio, Voss, & Shakir, 2007; Shakir & Layton, 2002). Three 
of these criteria seem particularly pertinent to the development of pharmacovigilance 
methods in our study: 
 The strength criterion reflects that strong associations are more likely to be causal 
than weak associations (Shakir & Layton, 2002). Quantitative statistical data 
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mining methods evaluate ADR signals from the strength of association point of 
view.  
 The plausibility criterion relates to evidence about mechanisms that may be 
involved to support a causal relationship.  
 The coherence criterion relates to the consistency of the hypothesis in question with 
contemporary medical knowledge. 
 
2.7 LBD and literature NLP annotation tools 
2.7.1 LBD and discovery patterns 
Processing published biomedical literature to uncover implicit relationships among entities 
is referred to as LBD (Bruza & Weeber, 2008; Swanson, 1986b, 1987; Weeber, Klein, de 
Jong‐van den Berg, & Vos, 2001). LBD involves finding new knowledge by analyzing the 
literature, rather than through scientific experimentation. This is accomplished by 
identifying hidden connections between entities described in the published literature 
(Swanson, 1986a, 1986b). The origins of LBD may be traced to the serendipitous discovery 
that fish oils can be therapeutically useful in the treatment of Raynaud’s syndrome (poor 
circulation in the peripheries) by information scientist Don Swanson (Swanson, 1986a, 
1986b). Weeber et al. described the two types of LBD (Weeber et al., 2001).  
One type, referred to as “open LBD”, starts from a known term or concept (generally called 
A, although also referred to as C in Swanson’s early work) and tries to find an interesting 
hypothesis in the form of a previously unrecognized connection to some other term. If an 
article argues that A is associated with B and a second article mentions that B is associated 
with C, A may treat C. For example dietary fish oil (A) affects platelet aggregation, blood 
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viscosity and vascular reactivity (B), and these biological factors (B) play a role in 
Raynaud's syndrome (C) (Swanson, 1986a). Consequently, it is reasonable to hypothesize 
that A treats C. The open LBD process proceeds from the source term A to an unknown 
target term C and culminates in the generation of a new hypothesis.  
The second type of LBD is referred to as “closed LBD”. In a closed LBD process the goal 
is to evaluate an existing hypothesis. Closed LBD starts with known terms A and C, with 
the goal to identify intermediate terms B that provide the bridge between A and C (Weeber 
et al., 2001). For example, in 1988 Swanson found intermediate concepts to explain a 
hypothetical relationship between migraine and magnesium (Swanson, 1988). Smalheiser 
and Swanson used closed LBD to propose an explanation for epidemiologic evidence that 
estrogen might protect against Alzheimer’s disease (Smalheiser & Swanson, 1996).  
LBD methodologies generally utilize statistical information derived from the frequency 
with which terms, or discrete concepts extracted from the literature using automated tools 
(e.g. MetaMap) or assigned to it by human annotators (Srinivasan & Rindflesch, 2002), co-
occur (Hristovski et al., 2006; Yetisgen-Yildiz & Pratt, 2006). This has been referred to as 
the co-occurrence model (Sehgal, Qiu, & Srinivasan, 2008). These co-occurrence statistics 
are interpreted by correlation-mining and ranking algorithms (Yetisgen-Yildiz & Pratt, 
2006, 2009).  
A limitation of these methods is that they generally do not consider the nature of the 
relationship between the terms or concepts concerned. To address this limitation, 
Hristovski and his collaborators (Hristovski et al., 2006) propose using semantic relations 
to eliminate spurious relationships introduced by frequently co-occurring concepts that are 
not meaningfully related. In their initial work, the semantic relations concerned were 
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extracted from the literature by two NLP systems: SemRep (Rindflesch & Fiszman, 2003) 
and (specifically to extract phenotypic information) BioMedLEE (L. Chen & Friedman, 
2004). Their approach involved the specification of “discovery patterns”, patterns of 
relationships between concepts that may indicate an implicit therapeutic relationship 
(Hristovski, Friedman, Rindflesch, & Peterlin, 2008). These conditions can be specified as 
sets of semantic predicates. For example, Ahlers et al. (Ahlers, Hristovski, et al., 2007) 
defined the May_Disrupt pattern as follows: 
Substance X <inhibits> Substance Y 
Substance Y <causes|predisposes|associated with> Pathology Z 
Substance X <may disrupt> Pathology Z 
Variants of this approach have been applied to generate or support the hypotheses that fish 
oil treats Raynaud’s disease (Hristovski et al., 2006), insulin treats Huntington disease 
(Hristovski et al., 2006), and antipsychotic agents prevent cancer (Ahlers, Hristovski, et 
al., 2007). Recently, this approach was also adapted to provide evidence to support the 
plausibility of an observed drug/ADR association (Hristovski et al., 2012a; Hristovski, 
Burgun-Parenthoine, Avillach, & Rindflesch, 2012b), providing proof-of-concept that 
LBD methods can be applied within the problem domain of pharmacovigilance. Regardless 
of the application domain, knowledge used to populate discovery patterns is extracted from 
the biomedical literature using NLP.  
2.7.2 Literature NLP annotation tools  
MetaMap and SemRep are two examples of tools that have been used to extract information 
encoded in the biomedical literature. MetaMap is a widely-used NLP tool that identifies 
concepts from the Unified Medical Language System (UMLS) in biomedical text (A. R. 
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Aronson & Lang, 2010; A. R. Aronson, 2001). SemRep (Rindflesch, Fiszman, & Libbus, 
2005; Rindflesch & Fiszman, 2003) is a rule-based NLP tool (A. R. Aronson & Rindflesch, 
1998) that draws on concepts extracted by MetaMap and medical domain knowledge in the 
UMLS to extract semantic predications (Rindflesch & Fiszman, 2003). Its input consists 
of sentences from the literature; its output is a series of semantic predications identified in 
the respective text. A semantic predication is a subject-predicate-object triple sentence in 
which the subject and object are UMLS concepts and the predicate is a semantic 
relationship. For example, metformin (UMLS Concept C0025598) TREATS diabetes 
mellitus (C0011849) is a semantic predication extracted from the phrase “Treatment of 
diabetes mellitus with metformin”. Evaluations of SemRep reveal a precision between 0.73 
and 0.81, and a recall of 0.55 on the biomedical literature (A. R. Aronson & Rindflesch, 
1998; Kilicoglu, Fiszman, Rosemblat, Marimpietri, & Rindflesch, 2010; Rindflesch & 
Aronson, 2002). Semantic predications benefit the LBD process in several respects. The 
additional information provided by semantic predications makes the LBD results easier to 
interpret. In addition, it has been noted that a large number of uninformative co-occurrences 
must be manually reviewed when LBD is based on lexical statistics alone (Lindsay & 
Gordon, 1999). In contrast, semantic predications provide the means to isolate relationships 
between concepts that are logically connected in a meaningful way. 
 
2.8 Semantic Vectors (Cohen & Widdows, 2009) 
Regardless of whether co-occurrence relations or discovery patterns are used, LBD systems 
must explore large numbers of co-occurring terms or possible reasoning pathways to 
identify explanatory hypotheses (for closed discovery) or previously unrecognized 
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relationships (for open discovery). Consequently, the process of LBD can be 
computationally expensive, and thus faces scalability issues in the context of the rapid 
growth of the biomedical literature. In contrast, the field of distributional semantics has 
produced corpus-derived statistical models that can measure the relatedness between two 
concepts by comparing vector representations of these concepts, called semantic vectors, 
that are derived from the contexts they have occurred in (Cohen & Widdows, 2009), 
without the need to explicitly explore co-occurring concepts once the initial model has been 
generated. Consequently, several authors have explored the use of distributional models 
for LBD (Cohen et al., 2010; Cole & Bruza, 2005; Gordon & Dumais, 1998).  
2.8.1 Overview of semantic vectors 
These geometrically motivated models of distributional semantics represent terms or 
concepts as high-dimensional vectors derived from the contexts in which they have 
occurred. Relatedness between a pair of terms or concepts is then estimated from their 
representing vectors’ similarity (Cohen et al., 2010). The vector components can be binary, 
ternary, real, or complex values (Kanerva, 2009; Widdows & Cohen, 2012).  
The overall methodology of semantic vectors is to build vector representations for terms 
and documents. Different methods exist to compute these vectors. For example, document 
vectors can be built from term-by-context matrices (Cohen & Widdows, 2009); in Latent 
Semantic Analysis (LSA) the initial representation is a term-document matrix derived from 
a corpus (Landauer & Dumais, 1997). 
Overall, document vectors are derived from the vector representations of the terms that 
they contain and as a consequence, documents with similar terms have similar vector 
representations. A mathematically computed distance between vectors is then 
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representative of the similarity of the documents they represent. A key aspect is that the 
abstract concept of meaning or semantics of a concept is converted into a metric that can 
be computationally exploited. 
Term-by-context matrices or term-document matrices can be large for text corpora with a 
high number of terms and documents. PubMed/MEDLINE for example has both dozens of 
millions of terms and documents. Deriving vector representations with term-by-context or 
term-document matrices can thus become computationally unfeasible. Methods to 
circumvent this problem by reducing the vector dimensionality have been conceived and 
shown to effectively preserve the meaning of the represented concepts as described in the 
next section. 
2.8.2 Scalability and random indexing (RI) 
RI, a relatively recent development for dimension reduction, supports the derivation of 
semantic distance from large corpora at minimal computational expense (Cohen & 
Widdows, 2009). RI further improves the scalability of distributional methods by avoiding 
computationally intensive approaches to dimension reduction of the original term-by-
context matrix (Kanerva, Kristofersson, & Holst, 2000; Kanerva, 2010). The algorithm’s 
computational complexity scales linearly with increasing size of the input data. It can be 
incrementally updated as new documents are added without retraining the whole dataset; 
thus it is applicable to large corpora such as MEDLINE. Two variants of RI have been 
applied to LBD in our previous work, which can efficiently infer and identify therapeutic 
relationships. One is Reflective Random Indexing (RRI) (Cohen et al., 2010), which 
models co-occurrence. The other one is Predication-based Semantic Indexing (PSI) 
(Cohen, Widdows, Schvaneveldt, Davies, et al., 2012), which implements discovery 
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patterns in vector space. On account of their scalability, these models permit inference on 
a scale that would be prohibitively time-consuming if explicit exploration of all possible 
reasoning pathways were attempted. This is accomplished through a mechanism known as 
“indirect inference” (Landauer & Dumais, 1997), which enables distributional models to 
find meaningful connections between terms that do not co-occur with one another directly, 
without the need to explore intervening terms explicitly. Further details about these two 
LBD distributional semantics models (RRI and PSI) are provided in Section 4.2.1 and 4.2.2 
respectively.  
 
2.9 Research opportunities 
2.9.1 Active drug surveillance with EHR 
With the broader availability of EHR data and the building of data repositories by 
integrating different EHR systems (FDA Science Board Subcommittee, 2011; P. Lopes et 
al., 2013; Platt et al., 2009; Stang et al., 2010), an active and real time pharmacovigilance 
surveillance may be achieved in the near future. This poses informatics challenges from 
the data integration perspective. With respect to EHR signal detection, the challenge of 
improving signal detection is likely to be a research focus. This can be achieved using 
statistical data mining methods, and by improving the accuracy of true drug/ADR co-
occurrence data using informatics methods.  
2.9.2 Using distributional semantic models to find plausible drug/ADR associations 
Signal evaluation is still a key pharmacovigilance challenge (P. Lopes et al., 2013). The 
proposal of substantiating and verifying ADR signals by analyzing the literature and 
existing drug-related knowledge bases in an automated fashion raises many research 
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questions. With the scalability of newer distributional semantics methods, and their 
capability of modeling the indirect relationships between entities using literature, I posit 
that LBD distributional semantics can retrieve evidence from the literature to establish the 
plausibility of connections between drugs and ADRs. This will assist the 
pharmacovigilance evaluation process by providing relevant evidence for domain experts 
to consider for causality assessment in signal evaluation.  
 
In the chapters that follow, I will evaluate this hypothesis by using state-of-the-art 
statistical algorithms to analyze an EHR system and identify statistically significant 
drug/ADR associations. Scalable LBD models based on distributional semantics are 
designed and built to leverage knowledge from the biomedical literature to identify 
plausible drug/ADR associations. An evaluation is conducted to determine the validity of 
each developed method.  
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Chapter 3: Signal Detection from Outpatient Electronic Health Record Data Using 
Statistical Mining 
Research suggests data collected by SRS are limited by long time latency, incorrect or 
incomplete clinical information, underreporting and reporting bias (Alvarez-Requejo et al., 
1998; Hasford et al., 2002). Clinicians and researchers have also utilized existing 
healthcare data sources such as Electronic Health Records (EHR) to attempt to identify 
previously unreported adverse drug reactions (ADRs) (Haerian et al., 2012; Harpaz et al., 
2013; Trifirò et al., 2009; Wang et al., 2009). However, these data are inherently noisy as 
drugs and potential side effects may co-occur in the EHR for many reasons. In addition, 
the EHR often contains free-text data, and the accuracy of Natural Language Processing 
(NLP) tools is not perfect. New methods are required to selectively identify potentially 
hazardous drug/ADR associations. Consequently, the development of computational 
approaches to more accurately detect potential side effects is currently an active area of 
research (Bauer-Mehren et al., 2012; Deftereos et al., 2011; Friedman, 2009; Oliveira et 
al., 2013; Shetty & Dalal, 2011). These approaches have predominantly focused on 
improving signal detection using statistical methods, machine learning or some 
combination thereof.  
Statistical methods employed mostly involve disproportionality analysis. Other statistical 
algorithm based on co-occurrence has also been explored to detect possible side effects 
from unstructured clinical notes. Both statistical methods are based on an independence 
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model (Wang et al., 2009; Zorych et al., 2011). Disproportionality measure was developed 
from SRS data and has been tested to be able to retrieve drug/ADR associations from EHR 
data (Liu, McPeek Hinz, et al., 2012; Zorych et al., 2011) under the premise that the 
observed co-occurrence of a drug and an event can be considered as the reported a possible 
drug/ADR association (Zorych et al., 2011). Other statistical algorithm based on co-
occurrence, originated from detecting the above-chance frequent occurrence of two entities 
from a text corpus, has also been demonstrated to be effective in retrieving possible 
drug/ADR associations from clinical corpus (discharge summaries in (Wang et al., 2009)). 
The motivation of using this algorithm is based on the hypothesis that a drug entity and a 
possible problem entity are more likely to appear together than random combinations of 
any drug entity and any problem entity (Cao et al., 2007; Wang et al., 2009).  
However, EHR data was not captured for the purpose of reporting side effects, and 
consequently there exists information other than drug related problems, e.g. drug treatment 
information (symptoms, indication, etc.). So researchers need to select a related cohort for 
investigating ADRs using EHR data. Liu et al. (Liu, McPeek Hinz, et al., 2012) selected 
drugs and corresponding abnormal laboratory results as possible side effects from 
inpatients structured clinical data as the cohort. Wang et al. (Wang et al., 2009) utilized a 
NLP tool to process unstructured clinical notes and only selected drug and possible side 
effects related to the processed sections as the cohort. Consequently, statistical methods 
and machine learning tools are utilized together to analyze unstructured clinical notes for 
finding possible drug/ADR associations.  
Structured (Liu, McPeek Hinz, et al., 2012) and unstructured (Wang et al., 2009) inpatient 
EHR data and structured outpatient (Honigman, Light, Pulling, & Bates, 2001; Honigman, 
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Lee, et al., 2001) EHR data have been demonstrated to be a possible data source to identify 
ADRs. However, to our knowledge, unstructured outpatient EHR data hasn’t been used for 
ADRs identification. OMOP preliminary results suggest that the performance of using 
EHR systems varies by data source (FDA Science Board Subcommittee, 2011). In this 
study, an unstructured outpatient EHR data is evaluated to be a feasible data source for 
detecting ADRs. Both disproportionality measures and other statistical algorithm based on 
co-occurrence are used to analyze the outpatient EHR data and find possible drug/ADR 
associations. Corresponding workflow is discussed.  
 
3.1 Materials 
3.1.1 Clinical data warehouse (CDW) 
The CDW was developed by the Center for Clinical and Translational Science (CCTS) at 
the University of Texas Health Science Center at Houston. The outpatient EHR system for 
UT Physicians (Allscripts), is hosted on CDW for clinical research usage. It contains 
medical records on approximately 364,000 patients treated by UT Physicians (Saitwal et 
al., 2012). The batch used in this experiment is 20130130 containing about ten-year clinical 
data until January, 2013 and 2,603,279 outpatient clinical notes. This large sample size 
provided by the EHR system may provide enough power to detect small frequency ADRs.  
This work is qualified for an IRB exemption and has been approved by the Committee for 
the Protection of Human Subjects. This project refers to HSC-SBMI-12-0226 – “Detection 
of adverse drug events from electronic health records”.  
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3.1.2 Medical language extraction and encoding system (MedLEE)  
MedLEE is a NLP system, designed to parse narrative patient reports into structured 
representations including UMLS codes for identified concepts (Friedman, Shagina, 
Lussier, & Hripcsak, 2004). Friedman et al (Friedman et al., 2004) report the recall of 
MedLee for UMLS coding of all terms from 150 randomly selected sentences -- selected 
from a text collection consisted of 818,000 sentences that were retrieved from de-identified 
patients’ discharge summaries -- as 0.77 compared with a reference standard which was 
determined by seven experts’ manual review. The precision of the system was reported as 
89% for encoding a second set of 150 randomly selected sentences from the text collection 
then subsequently validated by experts. Since the overall evaluation was conducted on the 
records from the same institution in which the NLP system was developed, performance 
may be lower elsewhere as NLP systems often must be adapted to new contexts.  
3.1.3 Side effect resource 2 (SIDER2 (Kuhn, Campillos, Letunic, Jensen, & Bork, 
2010)) 
SIDER2 is a publicly available database containing information on marketed medicines 
and their known adverse reactions (Kuhn et al., 2010). SIDER2 was used to construct a 
dataset for our experiment and as a reference standard to confirm whether a predicted side 
effect is a true adverse reaction. SIDER2 contains 996 drugs, 4,192 side effects, and 99,423 
drug/ADR pairs. Only those side effects and drugs that were contained in the EHR data 
were retained, leaving a total of 833 drugs, 2123 side effects, and 71,753 drug/ADR pairs.  
3.1.4 Hierarchical relationships between concepts from UMLS knowledge base 
The number of clinical notes for a problem was extended by grouping related concepts 
based on the UMLS semantic network and UMLS Metathesaurus, specifically the 
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MRREL.RRF ﬁle (U. S. National Library of Medicine, 2009). This file includes 
relationships between UMLS concepts found in the UMLS Metathesaurus, while the 
relationship can be synonym (SY), child (CHD), sibling (SIB), parent (PAR) and etc. By 
utilizing these ancestor-oﬀspring hierarchical relationships (Figure 3-1), all oﬀspring nodes 
for a SIDER2 ADR can be retrieved and subsequently are considered as related concepts, 
and their corresponding clinical notes are counted for the SIDER2 ADR. Take Breast 
Carcinoma as an example, Breast Carcinoma (C0678222) is a parent node of Mucinous 
Carcinoma of Breast (C1334807) and Lobular Carcinoma (C0206692), and a child node of 
Carcinoma (C0007097). This hierarchical relatedness can be used to group related concepts 
for Breast Carcinoma and consequently to count its clinical notes.  
 
 
Figure 3-1:  The example ancestor-offspring hierarchy relationships between UMLS 
concepts 
 
3.1.5 MEDication-Indication (MEDI) 
It was anticipated that co-occurring drugs and problems in the clinical notes might often 
be related therapeutically. Consequently, I evaluated the utility of an indication knowledge 
resource, MEDI (Wei et al., 2013), as a means to eliminate drug indications from 
consideration as potential side effects. MEDI is a medication indication resource that was 
extracted from a set of commonly used medication resources, including RxNorm, 
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MedlinePlus, SIDER2, and Wikipedia (Wei et al., 2013). MEDI drugs are represented by 
RxNorm codes, and indications are represented by ICD-9 codes. MEDI contains 3112 
medications and 63,343 medication-indication pairs (MEDI-Complete). Additionally, the 
MEDI high-precision subset (MEDI-HPS) was also created by only including indications 
that are retrieved from RxNorm or at least two of the three other resources. MEDI-HPS 
contains 2136 medications and 13,304 medication-indication pairs. The estimated 
precision of MEDI-HPS is about 92%.  
 
3.2 Methods 
3.2.1 Annotating the EHR data using MedLEE 
Drugs and co-occurring problems from medical records in the CDW were annotated by 
MedLEE. The medical records I utilized are free-text, unstructured clinical encounter 
documentations in outpatient setting. Each clinical summary was processed by MedLEE, 
resulting in an output that included UMLS-codes and semantic types for each extracted 
concept. Concepts denoted as a “medication” or “problem” were utilized as the source of 
potential side effects. Their occurrence at document level was recorded, to enable 
evaluation of the frequency with which a drug or a problem occurred in the EHR data.  
3.2.2 Construct test data set 
All SIDER2 drugs and side effects that are contained in the EHR data were utilized for the 
experiment. All selected drugs and ADRs are paired up to construct a SIDER2 drug/ADR 
test set. This resulted in a set of 1,768,459 drug/ADR relationships, 71,753 of which were 
true and 1,696,706 of which were false.  
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3.2.3 Retrieve co-occurrence data for SIDER2 test set 
Co-occurrence data for the SIDER2 drug/ADR test set were retrieved from the EHR system 
and is referred to as original co-occurrence data. By using the ancestor-offspring 
hierarchical relationships in UMLS knowledge base, for each SIDER2 ADR, the EHR 
clinical documents that contain this concept or this concept’s all related offspring concepts 
are considered as ADR positive reports. This may also improve statistical power since the 
prevalence of some side effects is relatively low. By doing so, a second set of co-occurrence 
data were retrieved for each SIDER2 drug/ADR test set and is referred to as descendent 
co-occurrence data.  
3.2.4 Statistical algorithms 
3.2.4.1 Disproportionality analysis 
After retrieving co-occurrence data for the drugs and ADRs that appear in the test set, a 
contingency table was constructed for each drug-problem pair. Disproportionality 
measures – reporting odds ratio (ROR), proportional reporting ratio (PRR), Yule’s Q 
(Yule), information component (IC), Multi-item gamma Poisson Shrinker (MGPS) -- were 
applied to identify statistically significant drug/ADR pairs (Table 2-1 in Chapter 2). If the 
observed occurrence / expected occurrence is more than a quantitative threshold (which 
varies across different disproportionality measures), the drug/ADR combination is 
considered as a signal.  
3.2.4.2 Other statistical algorithm based on co-occurrence 
To test independence, Chi-squared test can be applied to drugs and problem-related entities 
extracted from the EHR data using NLP (or structured data if available) to test the strength 
of the relationship between drugs and problems based on their paired and independent 
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observations in the dataset. There may exist interrelations between different drugs and 
different problems.  
The Chi-squared value reflects the magnitude of the dependence. However, traditional Chi-
squared statistics rejects most null hypotheses due to the large sample size (Cao et al., 
2007) which results in false positives. Zorych et al. (Zorych et al., 2011) has shown that 
there are large amount of false positive signals detected from EHR data. In Chi-squared 
test, each drug/ADR pair is tested separately without taking into account the multiple 
comparison. Multiple comparison refers that multiple drug/ADR associations hypotheses 
are tested from the same dataset simultaneously (Ahmed, Dalmasso, et al., 2010). 
Researchers have proposed statistical approaches to control error rates in multiple 
hypothesis testing. Among these, the false discovery rate (FDR) was introduced to measure 
the multiple-hypothesis testing error and has been successfully used in large-scale genomic 
studies to control false positive results (Benjamini & Hochberg, 1995; J. D. Storey & 
Tibshirani, 2003; J. D. Storey, 2002). FDR avoids the over-conservativeness of the 
standard Bonferroni approach to multiple hypothesis testing, and has proven to be powerful 
in identifying sparse signals from a large number of tests (Cai & Sun, 2009). For example, 
FDR is used to detect differential gene expression in replicated DNA microarray 
experiments, where unknown dependencies are likely to occur (J. Storey & Tibshirani, 
2001). On account of the proven utility of the FDR approach as a means to identify sparse 
signals from large datasets (Ahmed, Thiessard, Miremont-Salamé, Bégaud, & Tubert-
Bitter, 2010), I also used the Chi-squared test augmented with the FDR as measuring 
significance threshold. The FDR approach (J. D. Storey & Tibshirani, 2003) determines 
the statistical significance of a q value for each tested pair. q values are estimated from p 
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values, which measure significance in terms of the false positive rate. The false positive 
rate is the rate at which null hypotheses are rejected (false drug/ADR associations are 
predicted as positive by a statistical model). For example, a false positive rate of 5% means 
that on average 5% of the false drug/ADR associations will be predicted as positive by the 
statistical model. The q value measures significance in terms of false discovery rate, the 
rate at which statistically significant signals are, in fact, false drug/ADR associations. Table 
3-1 describes how overall accuracy or error is measured in m drug/ADR pairs testing.  
 
Table 3-1:  Overall error measure in FDR approach (J. D. Storey & Tibshirani, 2003) 
 Tested 
significant 
(Positive) 
Tested not 
significant 
(Negative) 
Total 
Null hypothesis is True 
(no relationship between drug 
and ADR) 
False Positive 
(FP) 
α (Type I 
error) 
True Negative 
(TN) 
m0 (FP+TN) 
 (# of true null 
drug/ADR pairs) 
Alternative hypothesis is True 
(has relationship between drug 
and ADR) 
True Positive 
(TP) 
False Negative 
(FN) 
β (Type II error) 
m1 (TP+FN) 
(# of true alternative 
pairs) 
Total S = 1 (FP+TP) 
(# of pairs 
tested 
significant) 
S = 0 m (m0+m1 || S=1 + 
S=0) 
(total drug/ADR 
comparisons) 
𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑟𝑎𝑡𝑒 =  𝐸[
𝐹
𝑚0
] ≤ 0.05 
𝑓𝑎𝑙𝑠𝑒 𝑑𝑖𝑠𝑐𝑜𝑣𝑒𝑟𝑦 𝑟𝑎𝑡𝑒 (𝐹𝐷𝑅)  = 𝐸[
𝐹
𝑆
] = 𝐸[
𝐹
𝐹 + 𝑇
] ≤ 0.05 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =
𝑚0 − 𝐹
𝑚0
 
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑇
𝑚1
 
𝑓𝑎𝑙𝑠𝑒 𝑑𝑖𝑠𝑐𝑜𝑣𝑒𝑟𝑦 𝑟𝑎𝑡𝑒 (𝐹𝐷𝑅)  = 𝐸[
𝑚0 ∙ (1 − 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦)
𝑚0 ∙ (1 − 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦) + 𝑚1 ∙ 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦
] 
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3.2.5 Filtering indications  
To evaluate the utility of existing knowledge of indication, the two MEDI lists were applied 
to exclude indication relationships from the false pairs and tested using the top 5 best 
performing statistical models using the original SIDER2 test set.  
 
3.2.6 Performance evaluation 
The performance for different statistical algorithms were calculated and compared using 
the original SIDRE2 test set. The best five performing models were advanced for testing 
with different MEDI interventions and procedures to group related concepts.  
 
3.3 Experimental design 
The CDW EHR clinical narratives were processed and annotated by MedLEE (Friedman 
et al., 2004) with default setting. MedLEE extracts biomedical concepts from the EHR and 
categorizes these into semantic types based on large lexicon. Within MedLEE’s annotated 
output, those entities labels as “medication” and “problem” were considered as candidate 
drugs and ADRs respectively. SIDER2 (Kuhn et al., 2013) was used to construct a 
drug/ADR reference standard (SIDER2 drug/ADR test set) by pairing up all drugs and 
ADRs that exist in both the EHR data and SIDER2 to generate a set of 71,753 true and 
1,696,706 false drug/ADR relationships. Since SIDER2 was extracted from package 
inserts by text mining tools, there may exist false drug/ADR associations because of the 
text mining error or over reporting of side effects (Duke J, Friedlin J, & Ryan P, 2011).  
Existing disproportionality measures and Chi-squared test with FDR for detecting 
drug/ADR associations from outpatient clinical notes were calculated and compared. In 
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this experiment, different thresholds (4, 6, 10, 25) of co-occurred drug/ADR reports were 
considered as the second condition to predict true drug/ADR associations.  
Clinical narratives may have different concepts representing a SIDER2 ADR. Clinical 
notes containing these related concepts can be retrieved to expand the examples available 
for each SIDER2 ADR. In addition, a co-occurring drugs and problems may indicate 
therapeutic relationships, the MEDI lists were used to filter drug indication relationships 
from drug/problem candidates. Overall, my experiments concerned three methodological 
variants: (1) the choice of statistical measure; (2) increasing the examples available for 
each potential ADR by grouping related concepts for a SIDER2 problem; and (3) filtering 
known indication relationships.  
 
3.4 Results 
3.4.1 Experiment dataset 
There are 2,603,279 clinical narratives (narrative notes in CDW updates to 01/30/2013) 
that were annotated by MedLEE. 2,325,614 notes that contain at least medication or 
problem were used for the experiment. There are 229 narrative types in this batch. 23.5% 
of the notes are labeled as “chart note” (Table 3-2). A chart note, also called as a progress 
note, is dedicated when an established patient is seen for a repeat visit.  
In the EHR system, there are 7780 drugs and 10,670 problems. For SIDER2 set, there are 
833 SIDER2 drugs that are also contained in the CDW, and 2123 SIDER2 side effects that 
are contained in the CDW. These overlapping drugs and problems between SIDER2 and 
CDW were used to build an evaluation set for the experiment. In this evaluation set, all 
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drugs were paired up with all problems. The true drug/ADR pairs are the pairs that are exist 
in SIDER2. The false drug/ADR pairs are the pairs that do not exist in SIDER2.  
 
Table 3-2:  Top 10 clinical documentation types in the EHR system 
clinical documentation 
type 
Number of narrative 
notes 
Percentage of total 
clinical notes 
Chart Note 546,025 0.235 
Clinical Note 180,192 0.077 
Clinical Summary-
RTF 
144,486 0.062 
Pre-Live Dictation. 120,295 0.052 
Telephone Note 118,701 0.051 
Nurse Note 113,253 0.049 
Est Patient 96,567 0.041 
Established 81,496 0.035 
New Patient 63,110 0.027 
UT Imaging. 60,419 0.026 
 
3.4.2 Query the co-occurrence data for experiment datasets 
For the drug/ADR pair in the evaluation set, the number of notes that contain the drug-of-
interest and ADR-of-interest were counted to quantify co-occurrence. As discussed 
previously, to improve the statistical power, the notes that contain related problems-of-
interest were also considered relevant notes when estimating the drug-problem co-
occurrence counts for this problem (so any drugs co-occurring with a taxonomically related 
problem would be counted as though they had co-occurred with the index problem). On 
account of the two options for measuring associations with respect to related problems, 
there are two contingency tables for each experiment set (original vs. descendent co-
occurrence).  
47 
3.4.3 Statistical results 
3.4.3.1 Performance results 
3.4.3.1.1 Performance of statistical algorithms with original co-occurrence data 
The performance of predicting true positives, precision, recall and F-measure for different 
statistical algorithms with different co-occurrence threshold are compared and plotted in 
Figure 3-2. The average precision is 0.1315±0.0105. From this, I can anticipate that 10-
15% of recovered signals from outpatient clinical notes can be true side effects. Chi-
squared statistics with FDR threshold is the besting performing model with an F-measure 
of 0.1826. The best 5 performing statistical models based on F-measure are used in the 
following analysis.  
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Figure 3-2: Comparison of ability of different performance metrics (R-ROR, P-PRR, Y-
Yule, C-Chi-square, F-Chi-square with FDR, M-MGPS) to recover SIDER2 side effects 
for different statistical algorithms with different drug/ADR co-occurrence threshold; top 
left, top right, bottom left, and bottom right are the comparison of number of true 
positives, precision, recall, and F-measure, respectively 
 
3.4.3.1.2 Effects of potential ontology intervention 
The best 5 performing statistical models from previous results were used in comparing 
their performance between original and descendant co-occurrence data (Figure 3-3). With 
the descendant co-occurrence data, the algorithms detect more true positives, but this was 
counter-effected by more false positives retrieved and leads to the decreased precision. 
Overall, the F-measure decreases with the descendant co-occurrence data (Figure 3-4).  
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Figure 3-3: Comparison of the predicted drug/ADR association count comparing between 
original and descendant co-occurrence set for best five performing statistical models (F2-
Chi-square with FDR and 25 co-occurrence; C-Chi-square with 25 co-occurrence; F1- Chi-
square with FDR and 10 co-occurrence; P-PRR with 10 co-occurrence; Y-Yule with 10 co-
occurrence); top left, top right, bottom left, and bottom right are the comparison of number 
of true positives, false positives, true negatives, and false negatives, respectively 
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Figure 3-4: Comparison of ability of different performance metrics to recover SIDER2 
side effects for best five performing statistical algorithms (F2-Chi-square with FDR and 25 
co-occurrence; C-Chi-square with 25 co-occurrence; F1- Chi-square with FDR and 10 co-
occurrence; P-PRR with 10 co-occurrence; Y-Yule with 10 co-occurrence); top left, top 
right and bottom are the comparison of precision, recall, and F-measure, respectively 
 
3.4.3.1.3 Effects of MEDI intervention 
In this test, I selected the five statistical models with the best F-measure and evaluated the 
effects of different MEDI interventions. Since I excluded indications from false pairs in 
the reference standard (Table 3-3), it is expected that this will decrease the number of false 
positives (consequently increasing the true negatives). However, the number of true 
positives will not be changed, so recall should not be changed either. The precision may be 
improved because of the decreasing of false positives, as may the F-measure. The results 
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of these experiments are shown in Figure 3-5 and 3-6 below, which present the filtering 
the indications can decrease the predicted false positives and correspondingly increase the 
precision and F-measure.  
 
Table 3-3: Number of false pairs that have been excluded as indications 
Reference Set true pairs false pairs Total pairs 
Without filtering out indications 71,753 1,696,706 1,768,459 
Filtering indication by MEDI-HPS 71,753 1,694,739 1,766,492 
Filtering indication by MEDI-
Complete 
71,753 1,690,353 1,762,106 
 
 
Figure 3-5: Comparison of the predicted drug/ADR association count with different 
MEDI filtering indications for best five performing statistical models (F2-Chi-square 
with FDR and 25 co-occurrence; C-Chi-square with 25 co-occurrence; F1- Chi-square 
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with FDR and 10 co-occurrence; P-PRR with 10 co-occurrence; Y-Yule with 10 co-
occurrence); top left, top right, bottom left, and bottom right are the comparison of 
number of true positives, false positives, true negatives, and false negatives, respectively 
 
 
Figure 3-6: Comparison of ability of different performance metrics to recover SIDER2 
side effects for best 5 performing statistical algorithms (F2-Chi-square with FDR and 25 
co-occurrence; C-Chi-square with 25 co-occurrence; F1- Chi-square with FDR and 10 
co-occurrence; P-PRR with 10 co-occurrence; Y-Yule with 10 co-occurrence) after 
filtering indications by different MEDI lists; top left, top right and bottom are the 
comparison of precision, recall, and F-measure, respectively 
 
3.5 Discussion 
This experiment demonstrated that unstructured outpatient data can be used as a data source 
for detecting drug/ADR associations. The statistical testing procedure is well established 
for signal detection and can be potentially improved by considering the error controlling 
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within multiple comparison setting. Filtering known therapeutic relationships from 
possible drug/ADR candidates can improve the overall performance; this should become a 
required component in pharmacovigilance using EHR data.  
This work has several limitations. MedLEE was used to extract medications and problems 
from the CDW EHR system. After reviewing the annotated problems, there were some 
unlikely problem terms such as “arms” or “legs”. These are less likely problems related to 
medications and maybe caused by NLP processing errors. Since the procedure is not tied 
to a specific NLP tool, there is also the possibility of selecting another NLP tool with better 
performance. With the improvement of NLP technology, this method should get better 
performance accordingly.  
There is no agreed-upon gold standard in the field of pharmacovigilance (Tatonetti et al., 
2012), and it has been pointed out that SIDER2 data set may contain false drug/ADR 
associations (Duke J et al., 2011). This is likely to affect the performance evaluation by 
including wrong validation data. In addition, SIDER doesn’t include all the drugs that were 
used in the EHR system. Possible causes include the usage of different drug names, new 
drugs being used in clinical practice and terminology mapping or NLP annotation errors. 
This further hints at the fact that a comprehensive and accurate reference set is needed for 
accurately evaluating pharmacovigilance systems or methods.  
By exploiting UMLS hierarchical relationships, sub-concepts for a SIDER problem can be 
grouped together and the pathways between those sub-concepts can be used to relate to the 
comprising SDIER2 problem concept. However, initial experiments didn’t show an 
improvement of the overall performance in the experiment. This does not however 
necessarily imply that grouping related concepts isn’t suitable for improving the signal 
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detection performance. To assess this better, future studies are needed to scrutinize the 
effects of subsumption and grouping of concepts that are related through a hierarchy. 
Ontological inference experiments should be used to group related concepts in a more 
controlled and accurate manner to determine the effects on signal detection performance.  
 
3.6 Conclusion 
Drug/ADR signals can be detected from the outpatient unstructured EHR data with existing 
disproportionality measures and Chi-square statistics with FDR. Filtering known 
therapeutic relationships from possible drug/ADR combinations can exclude confounding 
factors and improve the performance. With the precision of about 10-15% of evaluated 
SIDER2 by statistical algorithms, additional signal evaluation is needed for the detected 
drug/ADR signals.  
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Chapter 4: Using Knowledge Extracted from the Literature to Identify Plausible 
Adverse Drug Reactions1 
Over the last decade, drug safety data obtained from spontaneous reporting systems (SRSs) 
have been analyzed using quantitative data mining procedures to retrieve strongly 
associated drug/ADR pairs (Puijenbroek et al., 2003; Rawlins, 1988a, 1988b). These 
highlighted associations are subsequently reviewed and scrutinized by domain experts. 
Review by domain experts is required to evaluate a signal using their knowledge and 
judgment to find a signal with clinical significance. However, on account of the human-
intensive nature of this task, automated assistance is desirable. In this study, I attempt to 
partially automate this aspect of the signal evaluation process. I do so using methods that 
leverage knowledge extracted from the biomedical literature as a means to assess the 
plausibility of an observed drug/ADR association.  
 
4.1 Materials 
In this study, MetaMapped Medline Baseline (MMB) and Semantic MEDLINE Database 
(SemMedDB) were used to represent knowledge from the biomedical literature. Side 
Effect Resource 2 (SIDER2) was used as data set for drug/ADR associations. The Semantic 
Vectors package was used to build concept-based (RRI, Reflective Random Indexing) and 
                                                          
1 This chapter is published at: Shang, N., Xu, H., Rindflesch, T. C., & Cohen, T. (2014). Identifying 
plausible adverse drug reactions using knowledge extracted from the literature. Journal of Biomedical 
Informatics. 
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predication-based (PSI, Predication-based Semantic Indexing) semantic space models 
(Cohen et al., 2010; Cohen, Widdows, Schvaneveldt, Davies, et al., 2012). 
4.1.1 MMB and SemMedDB 
2012 MMB was used as a repository for concept-based modeling. The MMB contains 
20,494,848 articles included in Medline up to November, 2011 and contains 399,701 
distinct concepts. The SemMedDB V2.2 (semmedVER22) was used for predication 
modeling, which was processed with SemRep version 1.5. This was the current version 
when the experiments started. SemMedDB contains 22,252,812 citations included in 
Medline up to March 31, 2013 and contains 63,795,467 predications. There are 58 distinct 
predicates and 257,350 distinct concepts in SemMedDB. There are also negated 
predications in the SemMedDB repository (e.g. anticoagulant_therapy NEG_TREATS 
(does not TREAT) phlebitis). However, the number of negative predications is relatively 
small (1.2% of total predications) and consequently they were not included in the PSI 
model.  
4.1.2 SIDER2 
SIDER2 is a publicly available database containing information on marketed medicines 
and their known adverse reactions (Kuhn et al., 2010). SIDER2 was used to construct a 
dataset for the experiment and as a reference standard to confirm whether a predicted side 
effect is a true adverse reaction. SIDER2 terms were normalized by mapping drug and side 
effects terms to UMLS CUI with UMLS Terminology Services (UTS) API 2.0 (U.S. 
National Library of Medicine & National Institutes of Health, 2012). These UMLS CUIs 
were then subsequently searched in SemMedDB and MMB to retrieve the mapped UMLS 
concepts which are represented in SemMedDB and MMB.  
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SIDER2 contains 996 drugs, 4,192 side effects, and 99,423 drug/ADR pairs. Only those 
side effects and drugs that were represented in both the RRI and the PSI spaces were 
retained, so the reference set contains 959 drugs, 3,436 side effects, and 90,787 drug/ADR 
pairs. Each vector model’s search space was composed of vectors representing the SIDER2 
side effects. For the PSI model, SIDER2 drug/ADR pairs were also used as training data 
to infer predicate reasoning pathways.  
4.1.3 MEDication-Indication (MEDI) 
As I would anticipate connections in the literature between medications and diseases they 
treat, I evaluated the utility of another knowledge resource, MEDI (Wei et al., 2013), as a 
means to eliminate drug indications from consideration as potential side effects. MEDI is 
a medication indication resource that was extracted from a set of commonly used 
medication resources, including RxNorm, MedlinePlus, SIDER2, and Wikipedia (Wei et 
al., 2013). MEDI drugs are represented by RxNorm codes, and indications are represented 
by ICD-9 codes. MEDI contains 3,112 medications and 63,343 medication-indication 
pairs. Additionally, the MEDI high-precision subset (MEDI-HPS) was created by only 
including indications that are retrieved from RxNorm or at least two of the three other 
resources. MEDI-HPS contains 2,136 medications and 13,304 medication-indication pairs. 
The estimated precision of MEDI-HPS is about 92% (Wei et al., 2013).  
In the experiments, MEDI was used to eliminate drugs’ indications from the side effects 
search space. To do so, all terms representing drugs (RxCUI) and indications (ICD-9 codes) 
in MEDI were normalized to UMLS concepts, and then each drug’s indications were 
filtered from this drug’s search space. In many cases, there exist hierarchical relationships 
between concepts. For example, C0264702 acute myocardial infarction of apical-lateral 
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wall is a child node of C0155626 acute myocardial infarction. So in the experiments, I 
extended the MEDI list by aggregating the related concepts by different hierarchical 
relations. I tested these various extensions of the MEDI list as different MEDI 
interventions.  
 
4.2 Methods 
4.2.1 RRI 
RRI (Cohen et al., 2010) is a variant of RI adapted to enable the recognition of meaningful 
indirect associations. The variant of RRI I used for the experiments allows for the 
estimation of semantic relatedness between UMLS concepts, and proceeds as follows.  
First, all terms in the text corpus are assigned unique vector representations, known as 
elemental vectors. I will refer to the elemental vector for concept C as E(C) for the 
remainder of this manuscript. In accordance with the RI paradigm (Kanerva, 2009), 
elemental vectors are generated stochastically. In this way, RI creates unique fingerprints 
for all terms in the text corpus. The vector components can be binary, ternary, real, or 
complex values (Kanerva, 2009; Widdows & Cohen, 2012). In the experiments, I use 
32,000 dimensional binary vectors constructed in accordance with the Binary Spatter Code 
(BSC) (Kanerva, 1994), one of a family of representational approaches known as Vector 
Symbolic Architectures (VSAs) (Gayler, 2004; Kanerva, 1994, 1996; Plate, 1995). This 
dimensionality was selected based on the results of simulation experiments in previous 
research (Wahle, Widdows, Herskovic, Bernstam, & Cohen, 2012), which suggest that at 
this dimensionality around 2,000 unique elemental vectors can be superposed with low 
probability of the superposed product being closer to some other elemental vector in the 
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space than its component vectors. However, I did not attempt to optimize this parameter, 
and would anticipate some improvement in accuracy in exchange for the additional 
computational work required to perform these experiments at higher dimensionalities. In 
the BSC, elemental vectors are constructed by distributing an equal number of 1’s and 0’s 
at random across the dimensions of the vector concerned. Consequently, elemental vectors 
have a high probability of being orthogonal or close-to-orthogonal to each other, with 
orthogonality defined as a Hamming Distance (HD) of half the dimensionality of the 
vectors concerned (Kanerva et al., 2000; Kanerva, 1994, 1996).  
The next step is to generate vector representations of documents, by superposing the 
elemental vectors of the terms contained in these documents. With binary vectors, 
superposition is accomplished by keeping track of the number of 1’s and 0’s that have been 
added in each dimension, and assigning the value in this dimension using the majority rule, 
with ties split at random. I will refer to this operation by using the “+”symbol, with “+=” 
indicating a superposition that includes the vector on the left of the operator also (so 
DOC(D) += E(C) is equivalent to DOC(D) = DOC(D) + E(C), a common operation during 
training).  
In the experiments, this superposition is weighted using the Log-Entropy weighting 
procedure. The local term weight for term i in document j (lij) is derived from the frequency 
of a term in a document. The global weight for term i (gi) describes the frequency of the 
term within the entire text corpus. They are computed with Equation 1.  
This weighting scheme reduces the influence of high frequency terms that may be 
uninformative, and tempers the influence of terms that recur frequently within a single 
document (Dumais, 1991). Once document vectors have been generated (Equation 2), it is 
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possible to generate vector representations of concepts (in this case, or terms in the general 
case), known as semantic vectors. I will refer to the semantic vector for concept C as S(C). 
Semantic vectors are constructed by superposing vector representations of the documents 
a concept occurs in.  
 
𝐿𝑜𝑔𝐸𝑛𝑡𝑟𝑜𝑝𝑦(𝑡𝑒𝑟𝑚 𝑖, 𝑑𝑜𝑐𝑢𝑚𝑒𝑛𝑡 𝑗) = 𝑙𝑖𝑗 × 𝑔𝑖 
𝑙𝑖𝑗 = log(𝑡𝑒𝑟𝑚 𝑖, 𝑑𝑜𝑐𝑢𝑚𝑒𝑛𝑡 𝑗) = log(1 + 𝑡𝑓𝑖𝑗) 
𝑔𝑖 = 𝐸𝑛𝑡𝑟𝑜𝑝𝑦(𝑡𝑒𝑟𝑚 𝑖) = 1 − ∑
𝑝𝑖𝑗 × log 𝑝𝑖𝑗
log 𝑛𝑗
, 𝑤ℎ𝑖𝑙𝑒 𝑝𝑖𝑗 =
𝑡𝑓𝑖𝑗
𝑔𝑓𝑖
 
𝑡𝑓𝑖𝑗: 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑛𝑐𝑒𝑠 𝑜𝑓 𝑡𝑒𝑟𝑚 𝑖 𝑖𝑛 𝑑𝑜𝑐𝑢𝑚𝑒𝑛𝑡 𝑗 
𝑔𝑓𝑖: 𝑔𝑙𝑜𝑏𝑎𝑙 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑓𝑜𝑟 𝑡𝑒𝑟𝑚 𝑖 (𝑡𝑜𝑡𝑎𝑙 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑛𝑐𝑒𝑠 𝑜𝑓 𝑡𝑒𝑟𝑚 𝑖 𝑖𝑛 𝑡𝑒𝑥𝑡 𝑐𝑜𝑟𝑝𝑢𝑠) 
𝑛: 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑜𝑐𝑢𝑚𝑒𝑛𝑡𝑠 𝑖𝑛 𝑡𝑒𝑥𝑡 𝑐𝑜𝑟𝑝𝑢𝑠 
Equation 1: Log-Entropy weighting equation 
 
𝑆(𝑑𝑜𝑐)+= 𝐸(𝑡𝑒𝑟𝑚) ∙ 𝑙𝑜𝑐𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 ∙ 𝑔𝑙𝑜𝑏𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 = 𝐸(𝑡𝑒𝑟𝑚) ∙ 𝑙𝑖𝑗 ∙ 𝑔𝑖 
Equation 2: Generating document vectors with weighting procedure in RRI 
 
Superposition of binary vectors requires maintaining a “voting record” that keeps track of 
the number of 1’s and 0’s added in each dimension. When local and global weighting 
metrics are utilized, the “votes” may not be integer values. So, for example, if the vector 
1010 were added with a weight of 0.5, a straightforward implementation of the voting 
record would add 0.5 to the dimensions of the voting record corresponding to the 1’s, and 
subtract 0.5 from the dimensions corresponding to the 0’s. Normalization involves tallying 
these votes. After training is complete, those dimensions of the voting record with positive 
values would be assigned 1, those with negative values would be assigned 0, and those 
with a zero value would be assigned either 1 or 0 at random. In practice, however, it is 
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computationally inconvenient to maintain and update 32,000 real values to serve as a 
voting record for each semantic vector. Consequently, the Semantic Vectors package 
employs a binary matrix approximation of the voting record, which sacrifices some 
floating-point precision in exchange for computational efficiency. These implementation 
details are provided in (Widdows & Cohen, 2012). 
These operations are expressed concisely in the pseudo code in Figure 4-1, adapted from 
(Cohen et al., 2010). A schematic representation for RRI is shown in Figure 4-2. I used 
Semantic Vectors Version 3.7 to build RRI vectors. Once semantic vectors were 
constructed, the relatedness between drugs and ADRs was estimated as [1 −
2
𝑛
𝐻𝑎𝑚𝑚𝑖𝑛𝑔𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒(𝑥, 𝑦)]. Therefore, a ranked list of ADRs for each drug was 
provided.  
 
q := # total terms 
n := # dimensions, n := 32, 000 
p := # total documents 
m := # total UMLS concepts 
k := # terms in a speciﬁc document OR # documents related to a speciﬁc concept 
⊳ initialize elemental vectors E(T) 
for i < q do 
         generate a zero vector of dimension n 
         in E(Ti) arbitrarily set half of the zero dimensions to 1 
end for 
⊳ train document model (E(T), p) 
for j < p do 
         for term i in document j do 
                  DOC(Dj) + = E(Ti) × LogEntropy (term i, doc j) 
         end for 
         normalize (DOC (Dj)) 
end for 
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⊳ train concept model (DOC (D), m) 
for j < m do 
         for each of k documents concept j occurs in do 
                  S(Cj) + = DOC(Dk) 
         end while 
         normalize (S(Cj)) 
end for 
Figure 4-1:  The pseudo code for RRI model training process 
 
 
 
Figure 4-2: Schematic representation of RRI training and inference process 
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4.2.2 PSI 
4.2.2.1 Operations in PSI 
The PSI model provides the means to implement discovery patterns for LBD using 
distributional semantics (Cohen, Widdows, Schvaneveldt, Davies, et al., 2012; Cohen, 
Widdows, Schvaneveldt, & Rindflesch, 2012). This is accomplished by representing 
concepts and relationships extracted by SemRep as high-dimensional vectors using an 
adaption of RI. In previous work, PSI has been applied to discover therapeutic relationships 
(Cohen, Widdows, Schvaneveldt, Davies, et al., 2012) using a two-stage process of 
discovery by analogy: first a geometric operator is used to infer discovery patterns from 
known treatments, then the identified discovery patterns are used to infer previously unseen 
therapeutic relationships.  
In addition to the superposition operation described previously, the PSI model utilizes a 
binding operation. Binding (⊗) is a compositional operation that is provided by VSAs, 
such as the BSC (Gayler, 2004; Kanerva, 1996). Binding two elemental vectors generates 
a third vector, which is dissimilar from these two component vectors. The binding 
operation is reversible (release ⊘). With binary vectors, pairwise exclusive OR (XOR) is 
used to accomplish both binding (⊗) and release (⊘).  
4.2.2.2 PSI training process 
The training process for generating semantic vectors proceeds as follows: 
(1) Generate elemental vectors for all concepts and relations occurring in semantic 
predications; 
(2) generate a semantic vector for each concept, initially empty; 
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(3) for each predication (concept-predicate-concept), bind the elemental vector of one 
concept and the elemental vector of the predicate, and add this bound product to the 
semantic vector for the other concept. 
During step (3), a statistical weighting scheme is applied. For the predication C1 P C2, the 
semantic vector S (C2) is generated as shown in Equation 3.  
 
𝑆(𝐶2)+= 𝐸(𝐶1) ∙ 𝑃𝑓 ∙ (𝑖𝑑𝑓𝑃 + 𝑖𝑑𝑓𝐶1) 
Equation 3: Generating second degree of Semantic Vectors 
 
The global weight Pf is derived from the number of times that the predication occurs in the 
SemMedDB. The local weight idf (inverse document frequency of the concept C or the 
predicate P) reflects the occurrence of the concept across all documents. They are 
computed as shown in Equation 4. 
 
𝑃𝑓 = log(1 + 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑛𝑐𝑒𝑠 𝑜𝑓 𝑝𝑟𝑒𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝐶1  𝑃 𝐶2 
𝑖𝑑𝑓𝐶/𝑃 = log(
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑝𝑟𝑒𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑟𝑒𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑐𝑜𝑛𝑡𝑎𝑖𝑛𝑖𝑛𝑔 𝐶/𝑃
) 
Equation 4: Weighting procedure in PSI 
 
The pseudo code for PSI is displayed in Figure 4-3.  
 
q := # unique UMLS concepts and predicates from SemMedDB 
n := # dimensions, n := 32, 000 
p := # total predications 
k := # predications related to a speciﬁc concept 
⊳ initialize elemental vectors E (C) and E (P) 
for i < q do 
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         generate a zero vector of dimension n 
         in E (Ci) or E (Pi) arbitrarily set half of the zero dimensions to 1 
end for 
⊳train semantic model (E, p) 
for j < p do 
         predication j: C1 P C2 
         𝑆(𝐶1)+= 𝐸(𝐶2)⨂𝐸(𝑃 − 𝐼𝑁𝑉) ⋅ 𝑃𝑓 ⋅ (𝑖𝑑𝑓𝑃 + 𝑖𝑑𝑓𝐶2) 
         𝑆(𝐶2)+= 𝐸(𝐶1)⨂𝐸(𝑃) ⋅ 𝑃𝑓 ⋅ (𝑖𝑑𝑓𝑃 + 𝑖𝑑𝑓𝐶1) 
          
end for 
normalize S(C) 
           Figure 4-3: The Pseudo code for PSI model training process 
 
All concepts and relations were assigned a binary elemental vector of 32,000 bits in length. 
The semantic vector of each concept was generated by superposing bound products related 
to this concept, where the bound products were produced by binding the elemental vectors 
for the other concept and predicate elemental vectors in each predication this concept 
occurs in. The search space of SIDER2 side effects contains 3,436 ADRs.  
4.2.2.3 Inferring discovery patterns 
After training the semantic vectors, the PSI model can be used to infer discovery patterns 
by “releasing” the semantic vector of a drug using the semantic vector of its ADR.  
The bound product of the drug’s semantic vector and discovery patterns’ vectors can be 
subsequently used as a query vector to search the vector space of side effects. In this 
procedure, discovery patterns were inferred from all known drug/ADR associations. For 
each drug, the five discovery patterns that were most frequently inferred from all other 
drugs and their ADRs were retained.  
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The pathways connecting drugs to side effects may not be restricted to one middle term 
(and two predicates). In previous experiments predicting therapeutic relationships, 
performance was improved by including pathways of three predicates and two middle 
terms (Cohen, Widdows, Schvaneveldt, & Rindflesch, 2012). This is accomplished by 
generating a second-degree semantic vector for a concept, S2(concept), by adding together 
the (first-degree) semantic vectors of all concepts connected to it by a predicate of interest. 
In the experiments, the two most popular predicates from inferred double-predicate 
reasoning pathways -- INTERACTS_WITH and COMPARED_WITH -- were used to 
build second-degree semantic vectors S2. This vector is then used as an alternative starting 
point for the inference procedure. From this point, the five most frequently inferred double-
predicate reasoning pathways using the second order semantic vector of all other drugs and 
the (first order) semantic vectors of their ADRs were retained. As these inferred pathways 
connect to drugs through either INTERACTS_WITH or COMPARED_WITH, they are 
referred to as triple-predicate pathways. 
4.2.2.4 Applying discovery patterns to find possible ADRs (Step 5 in Figure 4-4) 
To combine query vectors for frequently inferred reasoning pathways into one search 
expression, I use a disjunction operation that originates in the quantum logic of Birkhoff 
and von Neumann, and was first applied to information retrieval by Widdows and Peters 
(Birkhoff & Von Neumann, 1936; Widdows & Peters, 2003). I define the disjunction of 
these five query vectors as a query subspace derived from them using a binary vector 
approximation (Cohen, Widdows, De Vine, Schvaneveldt, & Rindflesch, 2012) of the 
Gram-Schmidt orthonormalization procedure (Golub & Van Loan, 2012). The length of 
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the projection of some other vector in this subspace provides an estimate of vector-
subspace similarity. 
For the double-predicate discovery patterns model, a drug’s query subspace was 
constructed from this drug’s first-degree semantic vector bound to the vector 
representations of the five double predicate reasoning pathways most frequently inferred 
from other drugs. For the double- and triple-predicate discovery patterns model, a drug’s 
query subspace also included this drug’s second-degree semantic vector bound to vector 
representations of the five reasoning pathways most frequently inferred from the second-
degree semantic vectors of other drugs.  
The length of the projection of the semantic vector for a candidate ADR into a drug’s query 
subspace was used to estimate the relatedness between these entities, providing a ranked 
list of potential ADRs for each drug.  
Figure 4-4 provides an overview of the PSI-based analogical reasoning process in its 
entirety. 
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Figure 4-4: Schematic representation of PSI training and inference process. 
Triglycerides: TG; myocardial infarction: MI; INTERACTS_WITH: IW; 
COEXISTS_WITH: CoeW; ASSOCIATED_WITH: AW; COMPARED_WITH: ComW 
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4.3 Experimental design 
An overview of the experimental design is shown in Figure 4-5. The first experiment was 
conducted without knowledge of drug indications. The concept-based RRI model and 
discovery pattern-based PSI model were compared with respect to their ability to identify 
known drug/ADR associations. In the second experiment, the model with the best 
performance from the first experiment was used to evaluate the effect of eliminating known 
indications from the list of predictions.  
 
 
Figure 4-5: Experimental design in the detection of SIDER2 known ADRs using LBD 
distributional semantic models 
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4.3.1 Experiment 1 design 
Distributional semantic vectors were used to model MMB and SemMedDB. RRI vectors 
and PSI vectors formed the basis for the models of LBD concept-based co-occurrence and 
LBD discovery patterns, respectively. As MetaMap may retrieve many more concepts from 
a particular document than SemRep retrieves predications, I varied the RRI model to assess 
the extent to which observed effects were due to the advantage of a more extensive (albeit 
less structured) knowledge base. In one case, a RRI space was derived from only those 
sentences from which predications were extracted. Consequently, there are three 
distributional semantic models -- RRI built from documents (RRI-from-document group), 
RRI built from predication source sentences (RRI-from-predication group), and PSI built 
from predications. The PSI model was evaluated with two settings. In the first case, only 
two-predicate discovery patterns were considered (PSI-double group), while the second 
case considered both two- and three-predicate patterns (PSI-double+triple group). The 
elemental vectors for terms, which are not meaningfully related to one another, were used 
to implement a random baseline (Baseline group).  
With the RRI models, for each drug, related problems were sought by comparing each 
vector in the side effect search space to this drug’s vector representation.  
With the PSI model, SIDER2 known drug-side effect pairs were used to infer predicate 
paths. For the PSI-double group, each drug’s query subspace was built as the disjunction 
of the bound products between the drug and its five double-predicate reasoning pathways. 
For the PSI-double+triple group, each drug’s query subspace additionally included the 
second degree semantic vector of this drug bound to five triple-predicate paths. The five 
triple-predicate paths were retrieved by the extension of second degree semantic vectors of 
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drugs. Comparing a drug’s query subspace with each vector in the search space allowed us 
to infer the drug’s possible side effects.  
 
4.3.2 Experiment 2 design 
From preliminary results, I found that there were some indications in the inferred ADRs. 
So I hypothesized that excluding known indications for drugs from the search space would 
improve performance. I tested this hypothesis in the second experiment utilizing 
knowledge of drug indications from MEDI. In this experiment, I tested variants of the 
MEDI indication list using the best performing model from the first experiment (PSI double 
+ triple group). I extended the MEDI-complete and MEDI-HPS lists to include all 
offspring, or immediate offspring nodes based on the UMLS semantic network utilizing 
the MRREL.RRF file. This file includes relationships between UMLS concepts found in 
the UMLS Metathesaurus (U. S. National Library of Medicine, 2009). By utilizing these 
ancestor-offspring hierarchical relationships, I define an offspring node as a node that has 
a MEDI indication as an ancestor (regardless of the number of intervening nodes); and an 
immediate offspring node as a node that has this MEDI indication as its parent. 
In this procedure, I first normalized all MEDI terms. For MEDI drugs, I mapped each 
drug’s RxCUI to a UMLS CUI with the RxNorm API (U.S. National Library of Medicine 
& National Institutes of Health, 2014) and then searched the UMLS CUI in SemMedDB 
and MMB to retrieve the mapped UMLS concept. For MEDI indications, I mapped each 
indication’s ICD-9 term to a UMLS CUI using the UTS API 2.0 (U.S. National Library of 
Medicine & National Institutes of Health, 2012) and then subsequently searched for this 
UMLS CUI in SemMedDB and MMB to retrieve the mapped UMLS concept. After 
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normalizing MEDI terms, the hierarchical relation of synonym (SY), child (CHD), and 
sibling (SIB) in MRREL.RRF were used to find drugs’ MEDI indications extended 
offspring or immediate offspring. Consequently, there were six MEDI lists (Table 4-1). 
These MEDI lists were used to exclude indications from the side effect search space and 
were tested in the second experiment.  
 
Table 4-1:  Different groups by extending MEDI in experiment 2 
MEDI intervention Extension Procedure Experiment Group 
No MEDI None No-MEDI group 
MEDI-HPS 
indications for 
SIDER2 drugs 
None MEDI-HPS group 
All synonym (SY), child (CHD), 
and sibling (SIB), as well as their 
offspring.  
MEDI-HPS-offspring 
group 
Immediate synonym (SY), child 
(CHD), and sibling (SIB) 
relationships. 
MEDI-HPS-immediate 
offspring group 
MEDI-complete 
indications for 
SIDER2 drugs 
None MEDI-complete group 
All synonym (SY), child (CHD), 
and sibling (SIB), as well as their 
offspring.  
MEDI-complete-offspring 
group 
Immediate synonym (SY), child 
(CHD), and sibling (SIB) 
relationships. 
MEDI-complete-
immediate offspring group 
 
4.3.3 Performance measurements 
To evaluate performance, I used a number of widely used metrics. Precision measures the 
proportion of accurate ADRs in relation to the total number of ADRs retrieved (Salton, 
Fox, & Wu, 1983). To evaluate the precision at different points in a ranked list, I used 
average precision (AP, the average of the precision values measured at the point at which 
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each correct result is retrieved for one example (Manning, Raghavan, & Schütze, 2008)). 
Mean average precision (MAP) is the average of the AP across all drugs. Precision at k 
(Manning et al., 2008) measures the precision at fixed levels of retrieved results and 
emphasizes the importance of finding relevant results early. I evaluated precision at k=50 
(Pk=50). Recall represents the proportion of ADRs retrieved out of the total number of ADR 
associations in the reference standard (Salton et al., 1983).  
A “rediscovery” (true discovery) is defined as an adverse effect inferred by a vector model 
and subsequently confirmed by SIDER2 as a true prediction. Consequently, the median 
rediscovery rank for a particular drug approximates the point in the ranked list produced 
by a particular model at which half of the known adverse reactions for this drug were 
recovered.  
The AP and median rank of the rediscoveries across drugs were compared by the paired t 
test and the Wilcoxon matched-pairs signed-rank test, respectively.  
To measure the performance with respect to the true positive rate (TPR) and false positive 
rate (FPR), receiver operating characteristic (ROC) curve was plotted for all drug/ADR 
pairs for all models. Subsequently, a global area under the ROC curve (AUC, “global” 
indicates that the scores of all drug/ADR pairs were combined into a single curve) was 
calculated using AUCCalculator (Davis & Goadrich, 2006). For the model with the best 
global AUC, a drug-based AUC was also calculated and compared between drugs. 
 
 
4.4 Results 
4.4.1 Experiment 1 
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4.4.1.1 Inferring discovery patterns 
The most strongly associated double-predicate path was calculated for each known 
drug/ADR pair. In total, 90,787 predicate paths were inferred. Among them, there were 
1,485 unique predicate paths. The five most frequently inferred double-predicate paths 
were selected. Second degree semantic vectors for drugs were constructed by adding 
together the semantic vector representations of any concept occurring in a semantic 
predication with the drug in question, where the predicate type was either 
INTERACTS_WITH or COMPARED_WITH. The most frequently occurring double 
predicate paths and inferred triple predicate paths with corresponding examples are shown 
in Table 4-2. They are consistent across all drugs. Many of these paths are readily 
interpretable, and could support a plausible biological mechanism for a predicted effect. 
For example, INTERACTS_WITH:CAUSES-INV suggests a drug may interfere with 
some biological factor which may cause a side effect. COMPARED_WITH:CAUSES-INV 
can be used to identify similar side effects by comparing their drug class information as 
COMPARED_WITH often indicates a comparative evaluation across different drugs in the 
same therapeutic category. Triple predicate paths extend the connecting path for drugs and 
related ADRs.  
 
Table 4-2: The most frequent predicate paths in inferred discovery patterns 
double/triple-
predicate 
Example 
INTERACTS_WITH 
CAUSES-INV 
dipyridamole INTERACTS_WITH nitric oxide 
bradycardia CAUSES-INV nitric oxide 
75 
double/triple-
predicate 
Example 
ASSOCIATED_WITH 
COEXISTS_WITH 
rosiglitazone COEXISTS_WITH apolipoprotein a-ii 
apolipoprotein a-ii ASSOCIATED_WITH myocardial 
infarction 
COMPARED_WITH 
CAUSES-INV 
bisoprolol COMPARED_WITH metoprolol 
hypotension CAUSES-INV metoprolol 
ASSOCIATED_WITH 
INTERACTS_WITH 
rosiglitazone INTERACTS_WITH triglycerides 
triglycerides ASSOCIATED_WITH myocardial infarction 
ISA 
CAUSES-INV 
naproxen ISA calcineurin inhibitor 
toxic nephropathy CAUSES-INV calcineurin inhibitor 
INTERACTS_WITH 
INTERACTS_WITH 
ASSOCIATED_WITH 
rosiglitazone INTERACTS_WITH lyrm1 
lyrm1 INTERACTS_WITH fatty acids, nonesterified 
fatty acides, nonesterified ASSOCIATED_WITH 
myocardial infarction 
INTERACTS_WITH 
ASSOCIATED_WITH 
COEXISTS_WITH 
rosiglitazone INTERACTS_WITH glycerol-3-phosphate 
dehydrogenase 
glycerol-3-phosphate dehydrogenase COEXISTS_WITH 
succinate dehydrogenase 
Succinate dehydrogenase ASSOCIATED_WITH 
myocardial infarction 
COMPARED_WITH 
INTERACTS_WITH 
ASSOCIATED_WITH 
rosiglitazone COMPARED_WITH glycerophosphates 
glycerophosphates INTERACTS_WITH low-density 
lipoproteins 
low-density lipoproteins ASSOCIATED_WITH 
myocardial infarction 
COMPARED_WITH 
COEXISTS_WITH 
ASSOCIATED_WITH 
rosiglitazone COMPARED_WITH gw 501516 
gw 501516 COEXISTS_WITH high-density lipoprotein 
cholesterol 
high-density lipoprotein cholesterol 
ASSOCIATED_WITH myocardial infarction 
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4.4.1.2 Performance 
Results for different vector models are shown in Table 4-3. PSI-based models performed 
better than RRI-based models and both models perform better than the random baseline. 
The PSI-double + triple group outperformed all other groups. All differences in median 
rank and AP were statistically significant (as estimated by Wilcoxon’s signed rank test and 
paired t test respectively). Pk=50 for each drug was compared across groups using Pearson’s 
correlation. For variants of the same model (RRI or PSI), Pk=50 was highly correlated (0.75-
0.84). Correlation in Pk=50 between the PSI and RRI models was between 0.52 and 0.57, 
suggesting the potential to improve performance by combining results.  
 
Table 4-3: Results of precision and rank-based measures for different groups 
Group MAP Pk=50 for all drugs 
(global precision) 
Median Rank 
(n=3,436) 
AUROC 
median mean 
Baseline group 0.0300 0.0284 1708 1711.44 0.5021 
RRI-from-predication 
group 
0.0365 0.0469 1629 1651.08 0.5140 
RRI-from-document 
group 
0.0520 0.0784 1333 1454.30 0.5508 
PSI-double group 0.0591 0.0942 1233 1379.65 0.5973 
PSI-double+triple 
group 
0.0848 0.1410 808 1108.47 0.6841 
 
4.4.1.3 AUC 
Figure 4-6 and Table 4-3 present the global ROC curves for all models. ROC curve shows 
the tradeoff between sensitivity and specificity. The global AUC provides a cumulative 
estimate of accuracy, and is shown for each model in Table 4-3. PSI-double+triple group 
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has the best global AUC of 0.6841. I measured its AUC at the drug level (Figure 4-7). The 
mean and median AUC are 0.7102 ± 0.0752 and 0.7058 respectively. Figure 4-7 shows a 
plot of the AUC for each drug against the log of the number of predications in SemMedDB 
with this drug as subject. This suggests a trend in which performance is generally better for 
those drugs for which more knowledge is available in the database. Those drugs with an 
AUC of 0.8 or above tend to occur in 10,000 or more predications as subject. 
Note that the global AUC as a metric will be inflated by methods that incorporate category 
bias into their prediction (Akbani, Kwek, & Japkowicz, 2004; Liu, Wu, et al., 2012), a 
subject I will return to in the discussion section.  
 
Figure 4-6: ROC plot of true positive rate and false positive rate for all groups 
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Figure 4-7: Performance of AUC for all drugs by PSI-double+triple group 
 
4.4.1.4 Rediscovery results 
The results of this experiment are illustrated in Figure 4-8. This figure plots the number of 
rediscovered side effects (left Y axis) and the proportion of the valid side effects 
rediscovered (or global recall, right Y axis) for each model against the mean number of 
suggested potential ADRs (X axis) at different statistical thresholds. All distributional 
models outperform the random baseline.  
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Figure 4-8: Rediscovery plot for experiment groups 
 
With approximately 100 predictions per drug, baseline, RRI-from-predication, RRI-from-
document, PSI-double and PSI-double+triple group have a global recall of 0.029, 0.045, 
0.069, 0.088, 0.125, respectively.  
4.4.2 Experiment 2 
The PSI-double+triple model was the best performing model in the first experiment, and 
was selected to test the effects of using variants of the MEDI list as a way to exclude 
therapeutic relationships to reduce the number of highly ranked false positive predictions.  
Table 4-4 presents the performance of the PSI-double+triple model when different MEDI 
lists were used. The median rank of true positive predictions was lower when MEDI was 
used to exclude the indication from the search space for each drug. However, as median 
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rank is based on the rank of true positive results only, it does not consider known side 
effects that may have been excluded from consideration by the MEDI list. In contrast, MAP 
also measures whether true side effects have been excluded. Consequently, MAP in the 
MEDI-complete-immediate offspring was higher than other groups. Overall, AUC was 
highest for the MEDI-HPS-immediate offspring group. Of the models, only the MEDI-
HPS-immediate offspring group outperformed the baseline PSI model by all metrics, and 
the improvements in performance were small in comparison with the differences in 
performance between distributional models in experiment 1. All differences between all 
MEDI intervention groups and No-MEDI group in Pk=50 are statistically significant as 
measured by the paired t test. However, the improvement in cumulative accuracy is 
negligible.  
 
Table 4-4: PSI-double+triple model performance across all tests with different MEDI 
lists. Best results are in boldface. Performance exceeding the baseline (results obtained 
by the best PSI model without MEDI) is marked with an asterisk (*) 
Group MAP Pk=50 for all 
drugs 
Median Rank AUC 
median mean 
No-MEDI group 0.0848 0.1410 808 1108.468 0.6841 
MEDI-HPS group 0.0849* 0.1417* 807* 1107.595* 0.6839 
MEDI-HPS-offspring 
group 
0.0798 0.1283 765* 1050.745* 0.6813 
MEDI-HPS-immediate 
offspring group 
0.0866* 0.1444* 795* 1094.41* 0.6850* 
MEDI-complete group 0.0839 0.1401 809 1108.062* 0.6831 
MEDI-complete-
offspring group 
0.0673 0.0917 681* 953.761* 0.6737 
MEDI-complete-
immediate offspring 
group 
0.0889* 0.1467* 773* 1068.718* 0.6821 
81 
4.4.3 Plausibility evidence found by PSI discovery patterns approach 
In this paper, the association between rosiglitazone and myocardial infarction, a highly 
publicized ADR discovered after the drug was released to the market, is used to illustrate 
how evidence from the literature can be retrieved for the evaluation of plausibility by a 
domain expert. The term “myocardial_infarction” was ranked in the top 1% (rank=29) and 
top 1.5% (rank=50) of potential side effects for rosiglitazone by the PSI-double and PSI-
double+triple models respectively.  
Rosiglitazone is a thiazolidinedione (TZD) antidiabetic drug, used to treat type 2 diabetes 
mellitus as an adjunct to lifestyle changes (Cheung, 2010; Hamblin, Chang, Fan, Zhang, & 
Chen, 2009; Lygate et al., 2003). Since its approval by the FDA in 1999, rosiglitazone was 
prescribed 3.8 million times annually up to June 2009 in the United States (Shah et al., 
2010). A meta-analysis of clinical trials conducted by Nissen (Nissen & Wolski, 2007) in 
2007 suggested that the use of rosiglitazone was associated with a significant increase in 
the risk of myocardial infarction. This led to rosiglitazone’s withdrawal from the European 
market in 2010 and a rosiglitazone black-box warning in the U.S. (Berthet, Olivier, 
Montastruc, & Lapeyre-Mestre, 2011; Shah et al., 2010). In 2013, the FDA lifted some 
prescription restrictions in the U.S. market based on a reevaluation of the Rosiglitazone 
Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) 
trial (ClinicalTrials.gov Identifier NCT00379769) (U.S. Food and Drug Administration, 
2013), but the European suspension is still in effect at the time of this writing.  
Rosiglitazone is a nuclear peroxisome proliferator-activated receptor (PPAR-gamma) 
agonist. The mechanism through which rosiglitazone causes cardiovascular events is 
unclear, but is thought to be related to unfavorable effects on triglycerides, low-density 
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lipoprotein cholesterol (LDL-C) particle size and density, and greater affinity for PPAR-
gamma than other TZD drugs (Bourg & Phillips, 2012; Goldberg et al., 2005; Khanderia, 
Pop-Busui, & Eagle, 2008; Y. K. Loke et al., 2011). To evaluate the extent to which these 
hypotheses were consistent with information utilized by the PSI-double+triple model, I 
reconstructed the pathways of predicates and concepts that were consistent with the 
inferred discovery patterns used to make this prediction.  
For myocardial infarction, each discovery pattern that was used for the inference was used 
to search the indexed SemMedDB predications and find middle terms that connect 
rosiglitazone with myocardial infarction through the discovery pattern. The middle terms 
retrieved were ranked based on their inverse document frequency. Since the indexed 
SemMedDB predications contain the source literature ID (PMID), I also retrieved related 
literature evidence that supports the prediction.  
Consequently 108,100 unique predication pathways were retrieved through 8 unique 
predicate paths (Table 4-5) and with 1,601 distinct middle terms that connect rosiglitazone 
with myocardial infarction. Table 4-6 shows some example predication pathways that were 
composed of two or three predications. There were around 17 sentences providing evidence 
to support each predication on average. I analyzed middle terms’ semantic groups 
(Bodenreider & McCray, 2003) and list the sample with distinct predicate paths connecting 
with different semantic groups (Figure 4-9).  
Table 4-5: Reasoning pathways used to retrieve evidence from the literature for the pair 
rosiglitazone -- myocardial infarction 
Predicate Path 
COMPARED_WITH : COEXISTS_WITH : ASSOCIATED_WITH 
COMPARED_WITH : INTERACTS_WITH : ASSOCIATED_WITH 
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Predicate Path 
INTERACTS_WITH : COEXISTS_WITH : ASSOCIATED_WITH 
INTERACTS_WITH : INTERACTS_WITH : ASSOCIATED_WITH 
COEXISTS_WITH : ASSOCIATED_WITH 
INTERACTS_WITH : ASSOCIATED_WITH 
COMPARED_WITH : ASSOCIATED_WITH : COEXISTS_WITH 
INTERACTS_WITH : ASSOCIATED_WITH : COEXISTS_WITH 
 
Table 4-6:  Some example predications for possible mechanism of rosiglitazone causing 
myocardial infarction 
Middle term “LDL cholesterol lipoprotein”; 123 unique predication pathways; for 
example: 
rosiglitazone INTERACTS_WITH apolipoproteins_b (Brackenridge et al., 2009; 
Sarafidis et al., 2005) INTERACTS_WITH ldl_cholesterol_lipoproteins (Vessby, 
Kostner, Lithell, & Thomis, 1982) ASSOCIATED_WITH myocardial_infarction 
(Goldberg et al., 2005) 
rosiglitazone INTERACTS_WITH paraoxonase_1 (van Wijk et al., 2006) 
INTERACTS_WITH ldl_cholesterol_lipoproteins (Gupta, Singh, Maturu, Sharma, & 
Gill, 2011) ASSOCIATED_WITH myocardial_infarction (Tetsuro Yoshida et al., 
2010)  
Middle term “triglyceride”; 1515 unique predication pathways; for example: 
rosiglitazone COEXISTS_WITH triglycerides (Goldberg et al., 2005) 
ASSOCIATED_WITH myocardial_infarction (De Caterina et al., 2011; Friis-Moller et 
al., 2003; Kuller Lewis et al., 2002; Lekhal, Børvik, Brodin, Nordøy, & Hansen, 2010; 
Phillips, 1977) 
rosiglitazone INTERACTS_WITH triglycerides (Chao et al., 2000; Nadeau, Ehlers, 
Aguirre, Reusch, & Draznin, 2007) ASSOCIATED_WITH myocardial_infarction 
rosiglitazone INTERACTS_WITH glycerol-3-phosphate_dehydrogenase (Suzuki, 
Suzuki, Sembon, Fuchimoto, & Onishi, 2013) COEXISTS_WITH triglycerides (Im & 
Hoopes, 1983) ASSOCIATED_WITH myocardial_infarction  
Middle term “ppar_gamma”; 992 unique predication pathways; for example: 
rosiglitazone COEXISTS_WITH ppar_gamma (Egerod et al., 2009; Johnson et al., 
2000; Otake et al., 2011; Risérus et al., 2005) ASSOCIATED_WITH 
myocardial_infarction (Fliegner et al., 2008) 
rosiglitazone INTERACTS_WITH ppar_gamma (Gao et al., 2007; Kim, 2006; Lee, 
2003; Tsukahara, 2006; Tzameli, 2004) ASSOCIATED_WITH myocardial_infarction 
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rosiglitazone INTERACTS_WITH glycerol-3-phosphate_dehydrogenase (Suzuki et 
al., 2013) COEXISTS_WITH ppar_gamma (Muhlhausler, Duffield, & McMillen, 
2007) ASSOCIATED_WITH myocardial_infarction 
rosiglitazone INTERACTS_WITH glycerol-3-phosphate_dehydrogenase 
INTERACTS_WITH ppar_gamma (Ding, Nagai, & Woo, 2003) 
ASSOCIATED_WITH myocardial_infarction 
rosiglitazone INTERACTS_WITH resistin (Jung et al., 2005) INTERACTS_WITH 
ppar_gamma (Patel et al., 2003) ASSOCIATED_WITH myocardial_infarction 
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Figure 4-9:  The predications retrieved by reasoning pathway for rosiglitazone causing 
myocardial infarction with specifying semantic groups for concepts 
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There were 2,618 distinct predication pathways about “triglycerides”, “LDL-C” and 
“PPAR-gamma” specifying 247 unique middle terms. Drilling down, Figure 4-10 shows 
the connecting concepts between LDL-C and myocardial infarction that fall along the 
reasoning pathways employed by the PSI-double+triple model. In each reasoning pathway, 
the middle terms were ranked using inverse document frequency, to approximate the 
weighting used by the predictive model. For each predication in these pathways, the source 
sentences from the literature were retrieved. For example, the article “A comparison of 
lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes 
and dyslipidemia” (Boyle et al., 2002) explains that rosiglitazone increased triglycerides 
compared with pioglitazone and has different effect on plasma lipids which may contribute 
to heart disease. Figure 4-10 shows the middle terms retrieved to justify that rosiglitazone 
may cause myocardial infarction via LDL-C.  
The capacity to retrieve and organize knowledge in this way suggests a new paradigm for 
information retrieval in which information supporting a hypothesis of interest is 
automatically aggregated and organized at the conceptual level. However, as the number 
of assertions in the literature far exceeds the number of documents, further research is 
needed to develop methods through which to prioritize these assertions, and present them 
in a manner conducive to human consumption. 
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Figure 4-10: Middle terms that were retrieved by PSI discovery patterns involving LDL-
C 
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4.5 Discussion 
This study evaluates the ability of scalable LBD methods based on distributional semantics 
to rank the plausibility of connections between drugs and potential ADRs. I find that both 
the RRI and PSI models are able to retrieve known side effects of drugs, but PSI performs 
this task better, as one would anticipate given the additional information beyond co-
occurrence that it encodes. The PSI model can further provide the reasoning pathways that 
were used to link a drug to a predicted side effect. Consequently, relevant literature can be 
retrieved to support the predictions, and provided to experts for review. However further 
research is needed to develop approaches through which the assertions underlying the large 
numbers of reasoning pathways utilized by the model can be prioritized for expert review, 
as these are too numerous for exhaustive manual review. Ultimately, I aim to provide 
domain experts with essential evidence while preventing information over-load. Even 
though it is not the best performing model, the RRI model has the advantages of a simple 
training process and the availability of more data to draw upon (as MetaMap has higher 
recall for concepts than SemRep has for predications). Conversely, the PSI model has the 
advantage of modeling plausibility, a capability with the potential to assist expert clinical 
review for pharmacovigilance. In addition, the correlation analysis between groups 
suggests that RRI and PSI complement each other, and can potentially be combined to 
improve performance on this task.  
For predicting ADRs, several statistical models and Machine Learning (ML) algorithms 
have been evaluated against an edition of SIDER, or a subset of this repository. In addition 
to methodological differences, these approaches have leveraged different data sets and a 
variety of knowledge bases as a basis for making predictions. In the section that follows, I 
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will provide a review of these approaches, and the performance they have documented for 
the prediction of ADRs in SIDER. 
Pauwels et al. represented drugs using as features the presence or absence of chemical 
substructure components described in PubChem (B. Chen, Wild, & Guha, 2009). In 
addition to standard supervised ML approaches, they applied canonical correlation analysis 
(CCA), including a sparse variant that emphasizes a small number of informative features 
for each training example. These methods were used to predict SIDER side effects, with a 
reported global AUC of 0.8932 (Pauwels et al., 2011) on a set of 1350 ADR and 888 drugs, 
using fivefold cross-validation. 
Subsequently, Liu et al. applied five supervised ML algorithms to the same SIDER set. In 
addition to the PubChem-derived chemical substructure features used by Pauwels et al., 
features were drawn from DrugBank (Knox et al., 2011) (drug targets, transporters, and 
enzymes), KEGG (Kanehisa & Goto, 2000) (pathway information) and SIDER itself (drug 
indications and side effects). A classifier was built for each SIDER ADR, and the classifiers 
were then evaluated on 832 SIDER drugs (for which DrugBank IDs could be found) using 
fivefold cross-validation. The support vector machine (SVM) algorithm performed best 
with a global AUC of 0.9524 on the full SIDER dataset (Liu, Wu, et al., 2012). The authors 
attribute much of the improvement in performance by this and other metrics to the effects 
of incorporating SIDER side effects as features, suggesting that certain side effects have a 
tendency to co-occur in drug label data. 
Other authors have reported performance on subsets of SIDER using similar methods. For 
cardio-toxicity related ADRs in SIDER, a median AUC of 0.771 using SVM for prediction 
has been reported (Huang et al., 2011). In this case, features were selected from information 
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about intended drug targets in DrugBank, and information about off-target effects from an 
expanded protein-protein interaction network developed using gene ontology (GO) 
annotations. A SVM classifier was built for each evaluated ADR and cross-validated on 
SIDER. 
With respect to performance, two of these studies, Pauwels et al. (Pauwels et al., 2011) and 
Liu et al. (Liu, Wu, et al., 2012) report a global AUC of close to 0.9 or higher with the best 
of their methods. Though the results are not directly comparable as I made predictions on 
a per-drug rather than a per-ADR basis, the difference between the global AUC of these 
methods and that obtained with our approach seems large. However this difference in 
global AUC is misleading. As noted by Liu and colleagues in their paper, the imbalance 
between positive and negative examples across ADRs and the way in which the global 
AUC was calculated in this work leads to an apparent inconsistency between it and the 
other evaluation metrics presented. For example, Pauwels and his colleagues display the 
AUC across different ADRs in a series of box plots, which shows a median AUC for the 
best-performing method (by this metric) of slightly above 0.6. Acknowledging this issue, 
Liu et al. also report precision and recall for each evaluated method with, for example, 
precision of 0.66 and recall of 0.63 for SVMs with their maximal feature set. Notably, the 
AUC in this case was around 0.95. 
This apparent inconsistency can be explained by the effect of the prevalence of positive 
examples for each ADR on the prediction strength. This is readily apparent for simple 
algorithms such as Naive Bayes, where the prior probability of a given category is 
incorporated into the estimate. However, it is also an issue for more sophisticated 
algorithms such as SVM (Akbani et al., 2004) particularly when the imbalance between 
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categories is severe. This is the case for many of the ADR examples: Liu et al. report a 
positive to negative ratio of around 1:166 for 554 of the 1135 ADRs. So given the same set 
of features, instances in these cases are likely to receive a lower prediction score than those 
in balanced cases. When these scores are aggregated across examples to generate a global 
AUC, ML methods that incorporate the category bias will obtain an inflated global AUC 
on account of this tendency to assign lower scores to instances with few positive examples. 
However, as noted by Liu et al. and demonstrated by the other reported metrics, this AUC 
is not an accurate reflection of the ability of these models to detect positive examples. 
To simulate the effects of category bias on global AUC, I performed a simple experiment 
in which I multiplied the similarity scores produced by our model by the proportion of 
positive examples for each drug. This roughly approximates the effects of an accurately 
estimated prior class probability during cross-validation experiments. This resulted in an 
increase of our global AUC from 0.68 to 0.88. I do not present this result for the purpose 
of comparative evaluation, as our experiments are not directly comparable with prior ML 
work for other reasons I will subsequently discuss. Rather, I present it as an illustration of 
the disproportionate influence of category bias on global AUC, which underscores the 
issues with this evaluation metric raised by Liu et al. I trust it will also serve to dispel the 
misleading impression that the predictive accuracy of our methods is vastly inferior to that 
reported previously.  
As our method does not consider the number of ADRs associated with a particular drug, 
the global AUC and median AUC approximately agree with one another. Our median AUC 
(across all drugs) of 0.7058, which falls somewhere in between that reported by Pauwels 
et al. (Pauwels et al., 2011) (across all ADRs) and Huang et al. (Huang et al., 2011) (across 
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cardio-toxicity related ADRs only). On account of the difference in denominator these 
results are not directly comparable, but they do further illustrate the discrepancy between 
global and local AUC in models that are not agnostic to class imbalance. Arguably such 
agnosticism is desirable from the perspective of an expert review, as it is difficult to justify 
the assertion that those drugs with fewer known associated side effects should be 
considered less likely to cause some newly observed side effect (and vice versa). 
With respect to methodological differences, all of the above methods are supervised ML 
methods, and were applied to infer whether or not drugs were associated with each ADR 
from the features of other drugs known to be associated with this ADR. So the predictive 
models were generally customized on a per-ADR basis, for example by generating an 
individual classifier for each ADR in the case of SVM. In contrast, our approach infers a 
set of abstract reasoning pathways that were consistent across the drugs I evaluated. 
However, as illustrated by the absence of evidence across certain pathways in the 
rosiglitazone example, some pathways may be more predictive for particular medications 
or ADRs. So it seems likely that I could further improve our performance by incorporating 
supervised ML, a direction I plan to explore in future work. 
Our approach differs with respect to the knowledge sources utilized also. For example, 
KEGG and DrugBank are manually curated databases. Our knowledge base, SemMedDB, 
contains predications that have been automatically extracted by SemRep from the 
biomedical literature using NLP. Inaccuracies in language processing, or indeed in the 
literature itself may introduce sources of error that are not present in manually curated data. 
However, the scope of the literature is much broader than that of human-curated resources. 
Furthermore, as there is no agreed-upon gold standard for ADRs, different studies have 
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utilized different datasets as reference sets (Tatonetti et al., 2012). Our study employed 
SIDER2, which includes considerably more drugs and ADRs than SIDER1. 
This work has several limitations. The first of these concerns the use of SIDER2 as a 
reference standard. As SIDER2 consists of recognized side effects only, I cannot reliably 
distinguish between false positive signals and previously unknown ADRs. Furthermore, 
SIDER was compiled from package insert information by NLP tools (Kuhn et al., 2010), 
and as such may include side effects that seldom occur in practice or false associations that 
were caused by text-mining errors (Kuhn et al., 2013). While SIDER2 is sufficient to 
evaluate the hypotheses of the current work, in future work I plan to incorporate other data 
sources, such as EHR data and FDA reports. These data sources may provide additional 
evidence to support the assertion that an unknown drug/ADR pair is worth investigating 
further. Alternatively, they may provide the means to select a subset of the side effects in 
SIDER2 that have been observed frequently in practice as an additional evaluation set.  
Secondly, the MMB repository contains one year less literature than the SemMedDB 
dataset. There is a difference of 1,7579,64 citations (7.9% of SemMedDB dataset). These 
were the newest datasets at the time of the experiment. However the MMB repository has 
many more data points than SemMedDB. For example, more than 99.99% of citations have 
concepts extracted by MetaMap and 59.91% of citations have predications extracted by 
SemRep.  
Another concern is the existing knowledge about causal relationships between drugs and 
related ADRs from the literature. For our dataset (90,787 pairs), 45% of pairs (concerning 
953 drugs) co-occur directly in the MMB repository and 5% of pairs (concerning 693 
drugs) have direct causal relationship (drug CAUSES ADR) in SemMedDB. So PSI’s 
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accuracy is dependent upon its ability to meaningfully infer connections between concepts 
that were not previously linked in its database, a capacity that would be particularly useful 
as a means of assessing novel ADRs that had not previously been documented in the 
literature. RRI is also able to draw such inferences, but in this case more of its performance 
may be attributable to direct co-occurrence.  
Inspecting the middle terms that our model retrieved for rosiglitazone-myocardial 
infarction association (Figure 4-10), I found that at times uninformative high-level 
concepts, such as “genes” and “proteins”, were retrieved. In our study, I addressed the issue 
of uninformative high level concepts in two ways, both related to their propensity to occur 
relatively frequently in the corpus. Firstly I used a frequency threshold of 1,000,000 to 
exclude frequently occurring concepts contained in SemMedDB. The frequency of “genes” 
and “proteins” is less than the threshold and cannot be filtered. Secondly, I used a weighting 
procedure to reduce the influence of high-frequency terms on the training process. 
However, more sophisticated approaches to filtering are possible. Information concerning 
UMLS semantic types and position in the UMLS hierarchy could be used to develop more 
sophisticated approaches, to further filter out uninformative high-level concepts, which 
may improve performance.  
The predictions made by PSI depend upon assertions extracted from the biomedical 
literature. One concern about the extracted predications is that they may be implausible on 
account of NLP errors. Though SemRep has been optimized for precision, its precision is 
not perfect. For example, Kilicoglu and colleagues estimate the precision of SemRep to be 
around 0.77 (Kilicoglu et al., 2008). Based on this, and other published evaluations (Ahlers, 
Fiszman, Demner-Fushman, Lang, & Rindflesch, 2007; Kilicoglu et al., 2010), it is 
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reasonable to estimate that around three in four predications in the set are perfectly 
accurate. In many cases, inaccurate predications nonetheless indicate co-occurrence, which 
is also informative. The PSI-based analogical reasoning approach I have employed is 
robust to isolated language processing errors, as highly ranked predictions are based on 
assertions extracted from thousands of unique reasoning pathways. For example, for the 
rosiglitazone-myocardial infarction association, 108,100 unique predications were 
retrieved, spanning eight of the inferred reasoning pathways. On average, individual 
predications were supported by 17 excerpts from the literature. If I extrapolate from prior 
published evaluations of SemRep, the predication concerned would have been accurately 
extracted from around 12 of these excerpts. So it is likely that at least some of the evidence 
supporting each individual assertion is accurate. Moreover, as this method is distributional 
in nature, it does not require that these assertions be perfectly accurate. Rather, the 
frequency with which an assertion is extracted factors into the strength of its contribution 
to a reasoning pathway. Nonetheless, the biomedical literature may contain controversial 
assertions, or contradictory conclusions from different experts or different experiments. 
This is illustrated by the rosiglitazone (brand name: Avandia) case. In 2007, the FDA added 
a black-box warning for heart-related risks to Avandia based on a meta-analysis (Nissen & 
Wolski, 2007) and three other studies (U.S. Food and Drug Administration, 2007). In 2013, 
the FDA lifted certain Avandia prescribing restrictions based on the readjudicated results 
of the RECORD trial (R. D. Lopes et al., 2013; Mahaffey et al., 2013), claiming the initial 
concerns were overblown (U.S. Food and Drug Administration, 2013). This decision was 
condemned by one of the authors of the original meta-analysis (Thompson, 2013). 
Currently our models weight the contribution of assertions using statistics related to local 
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and global frequency. However, it would also be possible to weight the importance of these 
assertions based on some assessment of the reliability of the source. For example, in 
information retrieval experiments, an approach incorporating citation information was 
better able to identify articles considered as important in a pre-existing bibliography 
(Herskovic & Bernstam, 2005). Possibilities include weights derived from the citation 
count of the source article, the impact factor of the journal, or the nature of the experiment 
described. It is possible that weighting metrics of this source would improve the predictions 
of our models, and they also suggest approaches to prioritize the large numbers of 
assertions supporting our predictions for review by human experts. 
 
4.6 Conclusion 
In this research, an emerging, scalable method of LBD that uses distributional statistics to 
infer and apply discovery patterns was adapted to evaluate the plausibility of drug/ADR 
relationships for the purpose of pharmacovigilance. The effective application of large 
amounts of partially accurate biomedical knowledge to this problem was facilitated by the 
scalable and robust nature of approximate inference in geometric space. This approach was 
shown to be more effective than a comparable co-occurrence based baseline, and has the 
further benefit of permitting the retrieval of evidence underlying the assertions used by the 
system to make its predictions. Consequently, our approach provides the means to assist 
with expert clinical review by providing evidence supporting the plausibility of the 
connection between drugs and ADRs. Furthermore, the models I have developed can be 
applied to filter drug/ADR signals that are detected in spontaneous reporting systems or 
EHR data, a direction I plan to explore in future work.  
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Chapter 5: Toward a Reality-based Repository of Adverse Drug Reactions: 
Comparing SIDER2 with Side Events Encountered in Practice 
Recent informatics research has focused on the development and evaluation of automated 
approaches to pharmacovigilance (D. J. Almenoff et al., 2005; Andrew Bate, 2003; Wang 
et al., 2009). However, since the purpose of pharmacovigilance is to monitor and predict 
previously unknown side effects, there is no complete reference set with which to validate 
detected drug/ADR associations. Nonetheless, there is a need for such a gold standard in 
pharmacovigilance (Manfred Hauben & Aronson, 2007). For example, a reference set is 
required to evaluate a signal detection algorithm or validate the predictions of a 
pharmacovigilance system. As it is not practical to construct a large-scale validation set 
consisting of previously unknown side effects, common strategies involve validation 
against published drug reference book (Lindquist et al., 2000), drug safety related labelling 
changes (Manfred Hauben & Reich, 2004), curated reference sets (Coloma et al., 2013; 
LePendu et al., 2013; Ryan et al., 2012; Ryan, Schuemie, Welebob, et al., 2013), or large-
scale database of known drug/ADR associations (Kuhn et al., 2010).  
The EU-ADR (Coloma et al., 2013) and the Observational Medical Outcomes Partnership 
(OMOP) (Ryan et al., 2012; Ryan, Schuemie, Welebob, et al., 2013), major drug 
surveillance projects in Europe and America, systematically developed small curated 
reference sets for evaluating their new developed methods on drug safety surveillance with 
observational healthcare data (for example, administrative claims and EHRs). The EU-
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ADR reference standard (Coloma et al., 2013) contains 94 drug-event associations (44 
positives and 50 negatives). This was constructed based on literature, WHO VigibaseTM 
(WHO spontaneous reporting system (SRS)) and clinical adjudication. These associations 
were restricted to ten important events in pharmacovigilance and are adequately 
represented in the EU-ADR network. With the experiences of previous OMOP experiments 
and stakeholder interest, OMOP selected four events to construct a reference standard for 
methodology evaluation. The OMOP reference standard (Ryan, Schuemie, Welebob, et al., 
2013) contains 399 drug-event associations (165 positive controls and 234 negative 
controls) that were developed from drug labeling, Tisdale level of causative evidence 
review (James E. Tisdale & Douglas A Miller, 2010) and systematic literature review. 
These associations are also required to have sufficient representations in OMOP databases. 
These two reference standards have been applied to evaluate different statistical methods 
in discriminating true effects from false drug-event associations with the EU-ADR 
databases (Schuemie et al., 2012, 2013) and the OMOP databases (William DuMouchel, 
Ryan, Schuemie, & Madigan, 2013; Madigan, Schuemie, & Ryan, 2013; Norén et al., 2013; 
Ryan, Schuemie, Gruber, Zorych, & Madigan, 2013; Ryan, Schuemie, & Madigan, 2013; 
Suchard et al., 2013).  
In addition to the curated relative small reference sets, researchers have used the Side Effect 
Resource (SIDER) to serve as a gold standard in a large scale to validate detected ADRs 
or to evaluate drug-event signal detection systems (Deftereos et al., 2011; Saiakhov, 
Chakravarti, & Klopman, 2013; Yates & Goharian, 2013). SIDER contains information 
about the side effects of drugs that has been extracted from package inserts by text mining 
tools. However, there is reason to believe that SIDER may include false drug/ADR 
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associations, which would lead to inaccurate evaluation of the systems concerned. It has 
been argued that package inserts over-report with respect to side effects (Duke J et al., 
2011). Analysis of SIDER has shown that text mining errors may occur when processing 
the package insert; for instance, generic warnings have been mistakenly extracted from 
labeling information (Kuhn et al., 2013).  
Therefore, to use a large scale reference standard in pharmacovigilance evaluation, it is of 
interest to determine the extent to which the side effects reported in SIDER occur in 
practice. By limiting to the side effects that have sufficient representations in practice, false 
drug/ADR associations can be eliminated from SIDER and the predictive power of 
pharmacovigilance methods can be less affected by inadequate sample size of drugs or 
events. The information of practice usage can be obtained from a post-marketing SRS. A 
SRS is designed to collect anecdotal case reports. Even though they are not peer-reviewed, 
the case reports in SRSs can provide supporting evidence for possible drug/ADR 
associations (J. K. Aronson & Hauben, 2006). These collected data represent suspected 
drug/ADR associations reported by healthcare practitioners that observed a reaction in a 
patient under their care, by pharmaceutical companies that are mandatory required to report 
any collected side effects, or by consumers that may experience unpleasant reactions for 
drug treatments. Therefore, these reports provide anecdotal evidence that a side effect 
mentioned in a repository has occurred in practice.  
In this study, I evaluate the frequency with which SIDER2 (SIDER version 2) drug/ADR 
associations occur in reports submitted to the Food and Drug Agency (FDA) Adverse Event 
Reporting System (FAERS). The ultimate goal of this research is to develop a drug/ADR 
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reference set consisting of those label-derived side effects that have been observed in 
practice, for the purpose of pharmacovigilance research.  
 
5.1 Materials 
SIDER2 is a publicly available database containing information on marketed medicines 
and their known adverse reactions (Campillos, Kuhn, Gavin, Jensen, & Bork, 2008; Kuhn 
et al., 2010). The current version (SIDER2) was released in 2012, and was used for this 
study. The information in SIDER2 was extracted from drug labeling information (package 
inserts) using text mining tools and a side effects dictionary. The source of package inserts 
includes British Columbia Cancer Agency, Facts@FDA, FDA Center for Drug Evaluation 
and Research, FDA MedWatch, and Health Canada Drug Product Database (DPD). 
Labeling information is from clinical trials, post-marketing surveillance, etc. To construct 
the side effects dictionary (Kuhn et al., 2010), Coding Symbols for Thesaurus of Adverse 
Reaction Terms (COSTART) was used as a seed dictionary and then was expanded by 
extracting synonyms for the seed dictionary from the Unified Medical Language System 
(UMLS). To build SIDER drug-event associations, the drugs’ indications and side effects 
related sections were processed to extract terms that correspond to the side effects 
dictionary and the terms extracted from indications were subsequently excluded from 
drugs’ side effects. SIDER2 contains 99,423 drug-event associations for 996 drugs and 
4192 side effects.  
FAERS is a spontaneous reporting system database that contains information on adverse 
event and medication error reports that were submitted to the FDA by pharmaceutical 
companies, health professionals and consumers in the United States (Center for Drug 
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Evaluation and Research & U.S. Food and Drug Administration, 2012). FAERS database 
contains 332,346 distinct strings in the “drug name” field, and 16,272 distinct strings in the 
“reaction” field within 4,070,077 reports collected between 2004 to 2012 Q3. MetaMap is 
a widely-used NLP tool that identifies concepts from the UMLS in biomedical text (A. R. 
Aronson & Lang, 2010; A. R. Aronson, 2001).  
 
5.2 Methods 
5.2.1 Import SIDER2 and FAERS data in database 
SIDER2 was downloaded and imported into a local database. Distinct drugs and side 
effects were retrieved from the “meddraAvderseEffects” table. Publicly available FAERS 
quarterly data files (2004 to 2012) were downloaded from the FDA website (Center for 
Drug Evaluation and Research & U.S. Food and Drug Administration, 2014). I imported 
all data into a SQL database aside from the 2012q4 data, since the metadata used in this 
quarter were inconsistent with the database as a whole. The database contain 4,070,077 
FAERS reports. For this study, I used information in the “Drug” and “Reaction” tables.  
5.2.2 Parsing drug and side effect terms using MetaMap (Figure 5-1) 
2013 edition of MetaMap (MetaMap 2013 was used to process and annotate retrieved drugs 
and reactions and map them to UMLS concepts (U. S. National Library of Medicine, 2009) 
for the purpose of mapping between FAERS and SIDER2. MetaMap identifies matches 
between terms in text and candidate concepts from the UMLS. Each of these candidates is 
annotated with a confidence score, a Concept Unique Identifier (CUI), a preferred label, 
and one or more semantic types. The semantic types indicate the type of the concept. 
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Examples include “Pharmacologic Substance” or “Diagnostic Procedure”. Candidates can 
be assigned multiple semantic types. 
I manually reviewed distinct semantic types or semantic type combinations for MetaMap 
processed SIDER2 drugs and side effects and found out two features of drugs or side effects 
relevant semantic types. First, there are semantic types that are irrelevant to my research, 
such as “Organ or Tissue Function”, “Organism”, or “Activity”. Candidates of those 
semantic types were excluded. Second, a combination of semantic types could often 
contribute a more relevant classification. For example, the semantic type “Immunologic 
Factor” occurred very frequently and often was associated with concepts that were not 
relevant to drugs. However “Immunologic Factor” in combination with “Pharmacologic 
Substance” provided more insight, and identified a relevant candidate in the context of our 
study. Another example of semantic type combinations is a concept annotation that has a 
candidate with only one semantic type having a higher confidence score and a candidate 
with semantic type combinations having a less confidence score. The manual review 
revealed that candidates with combinations of certain semantic types yielded more relevant 
concepts. Consequently, restricting the result list by only accepting very specific semantic 
types or combinations may increase the relevance of the concepts identified by MetaMap 
to the study.  
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Figure 5-1:  The procedure for mapping SIDER2 and FAERS 
 
5.2.3 Mapping between SIDER2 and FAERS 
After annotating SIDER2 and FAERS with selected semantic types or semantic type 
combinations, corresponding CUIs were retrieved and used to find the matched FAERS 
drugs or ADRs for parsed SIDER2 drugs or ADRs. Figure 5-2 illustrates this process using 
the example drug “dipyridamole”. For this drug, 78 FAERS drug inputs were found.  
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Figure 5-2:  Procedure of mapping SIDER2 drugs/side effects to FAERS drugs/reactions 
using “dipyridamole” as an example 
 
5.2.4 Retrieve number of reports for mapped SIDER2 drug-side effect pairs and 
perform disproportionality analysis to find significant SIDER2 drug/ADR 
associations 
For each SIDER2 drug-side effect pair, I retrieved the number of related FAERS reports 
through their mapped FAERS drugs or reactions. Then I constructed a contingency table 
for each drug-side effect association with corresponding FAERS terms. Disproportionality 
measures were used to calculate the significance of the association between drug and side 
effect pairs co-occurring in the FAERS reports. These methods operate under the 
assumption that if a drug causes a side effect, this drug and this event are more likely to 
appear together than random combinations of drugs and suspected adverse events in the 
SRS reports (Cao et al., 2005). 
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Routinely used disproportionality measures for pharmacovigilance drug-side effect signal 
detection include the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), 
Yule’s Q, and relative risk (RR) (Balakin & Ekins, 2009; Cao et al., 2007; Emmanuel Roux 
et al., 2005; van Puijenbroek et al., 2002). In addition to these measure, I applied Chi-
square test with the False Discovery Rate (FDR), which was introduced to measure the 
multiple-hypothesis testing error and has been successfully used in large-scale genomic 
studies to control false positive results (Benjamini & Hochberg, 1995; J. D. Storey & 
Tibshirani, 2003; J. D. Storey, 2002).  
5.2.5 Performance measure 
Descriptive statistics of agreement for drug-side effect relationships between SIDER2 and 
FAERS were estimated. We also conducted a manual review of a random sample of 60 
pairs that occurred in SIDER2 without accompanying FAERS reports, to investigate the 
cause of this mismatch. DailyMed was used to retrieve drug package inserts and review 
the “Adverse Drug Reaction” section to track down the side effect of interest. MEDLINE 
was queried to find published literature or case reports that relate to the drug/ADR pairs 
retrieved from the package inserts.  
 
5.3 Experimental design 
To identify the subset of SIDER2 drug/ADR pairs that have been reported in practice, I 
compare these pairs with anecdotal evidence from FAERS reports (Figure 5-3). To map 
SIDER2 drugs to text in the FAERS “drug” field, and SIDER2 side effect to text in the 
FAERS “reaction” field, MetaMap 2013 was used to process all terms and a manual review 
process of selecting related semantic types that (Figure 5-1) was used to select appropriate 
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UMLS candidates. Multiple disproportionality analysis methods (A. R. Aronson & Lang, 
2010; A. R. Aronson, 2001; Center for Drug Evaluation and Research & U.S. Food and 
Drug Administration, 2012) were then applied to analyze the significance of co-occurring 
drug-side effect associations. The significantly reported SIDER2 drug/ADR associations 
that are detected by all disproportionality measures are considered as a pharmacovigilance 
reference standard.  
 
Figure 5-3:  Study design for decreasing false SIDER2 drug-side effect associations 
 
5.4 Results 
5.4.1 Concept extraction 
Using the mapping procedure, I mapped 99% (986/996) of SIDER2 drugs and 97% 
(4072/4192) of SIDER2 side effects to UMLS concepts; 78% of FAERS drug strings 
(259,806 drugs) and 98% of FAERS reaction strings (15,989 reactions) to UMLS concepts.  
Among SIDER2 mapped UMLS concepts, 969 drugs and 3853 side effects were mapped 
to FAERS drug and reaction inputs. These concepts constituted 94.85% (94,306) of the 
SIDER2 drug/ADR pairs, which were subsequently compared with FAERS reports. Of 
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these 94,306 SIDER2 drug-side effect pairs, 11,306 pairs do not co-occur in FAERS 
reports. 83,000 drug/ADR pairs have co-occurring reports in FAERS database.  
For this study I only included reports that were related to these UMLS concepts. 
Consequently, 4,070,225 reports were used for disproportionality analysis.  
5.4.2 Reported SIDER side effects 
I analyzed the frequency distribution of reports related to 83,000 SIDER2 drug/ADR pairs 
that have co-occurred in FAERS reports (Figure 5-4). The number of FAERS reports 
ranges from 1 to 360,146, with mean of 1944, median of 85, 1st quartile at 14, and 3rd 
quartile at 598. The histogram of representing all pairs has long right tail and data are 
skewed. For a more granular picture of this distribution, I plotted the histogram for each 
quartile (Figure 5-4). Most drug/ADR pairs have a relatively small number of FAERS 
reports and less than 600 FAERS reports.  
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Figure 5-4:  Frequency distribution of SIDER2 drug/ADR pairs (y-axis) that are grouped 
by the number of FAERS reports that contain the drug/ADR of interest (x-axis) 
 
5.4.3 Statistically significant drug/ADR pairs detected by disproportionality 
measures 
I evaluated the significantly reported instances of SIDER2 drug/ADR associations by 
applying disproportionality measures using FAERS data (Table 5-1). About 60% to 80% 
of SIDER2 drug/ADR pairs met the thresholds for significance of these statistical 
measures. 46,203 SIDER2 pairs (904 drugs, 2984 side effects) were detected as statistically 
significant by all statistical metrics.  
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Table 5-1:  The percentage of statistically significant SIDER2 drug/ADR pairs using 
disproportionality measures 
ROR-1.96SE>1 PRR-1.96SE>1 YulesQ-
1.96SE>0 
IC-2SD>0 Chi-Square test 
with FDR (q 
Value<0.05) 
60%  
(50,139/83,000) 
60.9% 
(50,570/83,000) 
61.4% 
(50,978/83,000) 
55.7% 
(46,209/83,000) 
79.7% 
(66,178/83,000) 
 
5.4.4 Manual review sample drug/ADR pairs without case reports 
I randomly selected 60 drug/ADR pairs from 11,306 pairs that were not included in any 
FAERS report and analyzed possible reasons for why there are no case reports (Figure 5-
5). Only 25 pairs were listed as side effects in the drug labeling or package inserts. Among 
those 25, eight side effects were listed as “infrequent side effects” or less than 1% of tested 
patients. For three side effects, the trial provided limited evidence whether they were 
caused by the drug under trial. In two instances (cidofovir related hypophosphatemia and 
glycosuria), participants were on several other medications and so it is difficult to establish 
the causal relationships. In another instance (teniposide related arrhythmia), there was only 
one report of this complication during pre-marketing trials, it was presumed rather than 
confirmed clinically, and it had occurred in an elderly patient with a variety of other health 
problems. Another six pairs among the 25 pairs had either mild side effects (e.g. dry throat, 
dizziness), or concerned a rarely prescribed drug (e.g. maraviroc). I could not find a 
plausible explanation for the remaining eight side effects that did not occur in any FAERS 
report; these side effects were listed in “Adverse Reactions” section for different systems 
without frequency information in the package inserts.  
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Among the remaining 35 drug/ADR pairs, six did not concern drugs; they instead 
concerned a vitamin or some other chemical component. So no package insert was 
available specifically the six chemical components (e.g. 1,25-dihydroxyvitamin D3, 
betaine). For seventeen pairs package inserts were available, but the labeling does not list 
the side effects concerned. Four pairs suggested a possible text mining error, as SIDER2 
side effect was close to the information in the labelling either conceptually or 
orthographically, but is, in fact, not a match. For four pairs that are drugs (e.g. ofloxacin), 
I couldn't find the package insert in the DailyMed database.  
 
Figure 5-5:  Interpretation of 60 randomly selected SIDER2 pairs without any supporting 
reports 
 
5.5 Discussion 
The study suggests that a higher precision subset of SIDER2 pairs could be identified by 
filtering out possible false positives using an inclusion criterion based on statistically 
significant association in the FAERS data. These false positives may result from NLP 
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errors during the parsing of drug labeling or inserts; on account of the inclusion of 
infrequent side effects that were not conclusively linked to the drug, but nonetheless 
occurred during clinical trials; or for other reasons. For the evaluation of new methods in 
pharmacovigilance it is imperative to use a high quality data set. If a data set used as a gold 
standard contains uncertainties itself the performance assessment of a new system or 
algorithm against these data set is difficult. It cannot be clearly concluded as to why the 
results of a new method show a certain outcome. Both a bias towards good or bad results 
could be caused by the quality of the reference data rather than by the method itself. 
Furthermore, in the case of machine learning systems trained on these data, the inaccuracies 
inherent in the data set may impair the performance of the derived models. 
There are some limitations to this study. With the mapping procedure, it frequently 
occurred that input strings, specifically those of reactions, were mapped to multiple 
concepts. This was the case when either no concept existed that expressed the entirety of 
the input, or MetaMap simply could not recognize it. For example, “carcinoma of the small 
bowel” exists as a concept in and of itself, even though it is a combination of carcinoma as 
a clinical observation and small bowel as a body location. On the other hand, for “splenic 
embolism” MetaMap lists a candidate concept for each of embolism and spleen. The 
spleen, which is of semantic type “Body Part, Organ, or Organ Component” is certainly 
not an appropriate result for splenic embolism, while the embolism itself is too general as 
it may appear at other body sites also. So rather than accepting “embolism” by itself, a 
combination of those two concepts would be most appropriate. The main concept, 
embolism in the example, and one or more concepts that contribute, modify, or tag the 
main concept could be combined. Similarly, for the input string “neutrophil count 
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increased” MetaMap detects “neutrophil count” as “Laboratory Procedure” and 
“increased” as “Quantitative Concept” but without connection to the neutrophil count. 
Considering a combinations of concepts of different semantic types that MetaMap treats as 
atomic units may improve the quality of our results.  
It also has been argued that SRSs are vulnerable to bias, and that the ADR under-reporting 
rate is considerable. Heterogeneity and bias result from different reasons: severe effects 
were more reported than mild ones, and labeled adverse drug reactions are more likely to 
be reported than unlabeled ones (Benjamini & Hochberg, 1995). The first of these findings 
is supported by our interpretations of 60 randomly selected SIDER2 drug/ADR pairs 
examined without FAERS reports, as some of these side effects were mild in nature. That 
labeled side effects are more frequently reported supports our argument for the use of 
FAERS reports as a means to validate drug/ADR repositories. 
An important outcome of this study is a high-precision subset of SIDER2 in which reported 
drug/ADR pairs are supported by the statistical significance of their FAERS reports. I 
anticipate that this subset will be of value for the training and evaluation future 
pharmacovigilance systems and new ADR signal detection algorithms.  
 
5.6 Conclusion 
Based on the consistency between FAERS and SIDER2 drug/ADR associations, a 
drug/ADR reference set is retrieved. The utility and application of the reference set will be 
further evaluated in pharmacovigilance research.  
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Chapter 6: Improving Signal Detection from the Electronic Health Records by 
Using Literature Based Discovery 
In previous experiments, I demonstrated that (1) possible drug/ADR signals can be detected 
from EHR data; and (2) LBD models based on methods of distributional semantics can 
identify plausible ADRs. In this experiment, I test my unifying hypothesis that signal 
detected from EHR data can be improved by integrating knowledge from the literature. 
Specifically, I propose that the performance of signal detection from the EHR can be 
improved by reranking the detected signals using LBD models based on distributional 
semantics. I evaluate this procedure using the drug/ADR reference set that we developed 
from SIDER2 and FAERS, as well as with SIDER2 itself.  
 
6.1 Experimental design (Figure 6-1) 
In Chapter 3, I described how Drug/ADR signals were detected from EHR data hosted in 
a Clinical Data Warehouse (CDW) using several disproportionality measures and other 
statistical tests. The best performing statistical model from those experiments was chosen 
for this one. Likewise, the best performing LBD model from the experiments described in 
Chapter 4 was utilized for this experiment. To perform the experiment, drug/ADR signals 
were detected in EHR data using the statistical model and ranked in accordance with the 
strength of their associations (according to the statistical model). These drug/ADR signals 
are referred to as pre-reranking drug/ADR signals. Subsequently, these signals were 
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reranked in accordance with the similarity scores (the measure for plausibility) that the 
LBD distributional model estimated from the relatedness between drugs and ADRs across 
the set of discovery patterns identified in the experiments described in Chapter 4. 
Consequently, these are referred to as post-reranking drug/ADR signals. They were then 
evaluated by comparing the pre- and post-drug/ADR signals to both SIDER2 and a 
reference set that we developed from it.  
 
 
Figure 6-1: Overall research design for reranking statistically significant drug/ADR 
associations by similarity scores 
 
6.2 Materials and Methods 
6.2.1 Models selected for this study 
I have elaborated methodologies for statistical data mining from EHR and LBD 
distributional semantics in Chapter 3 and Chapter 4, respectively. Of these methods, the 
Chi-square statistics with FDR (for estimating the statistical significance of observed 
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associations) and PSI double+triple group were best performing models in their respective 
experiments, and consequently were utilized for this one.  
In pre-reranking drug/ADR signals, the chi-square score is used as to reflect the statistical 
strength of the association observed in CDW data. The FDR-based q values are used as a 
significance threshold, to predict if the signal is true or false. Similarity scores from PSI 
double+triple model are used to rerank those signals that fell above the q-value threshold.  
6.2.2 Experimental reference standards and test dataset 
I evaluated the above models using two reference standards – side effect resource 
(SIDER2) and the reference set I developed using SIDER2 and FDA adverse event 
reporting system (FAERS, as described in Chapter 5). The reference set is relatively small 
and contains only those SIDER2 relationships that frequently occurred in SRS databases. 
For each reference standard, its drugs and side effects that are not only contained in the 
CDW EHR data but also represented in the PSI model were eligible for this experiment. 
This resulted in a set of 811 drugs and 1879 ADRs with SIDER2 and 773 drugs and 1374 
ADRs with the reference set (Table 6-1). Among these, only the predicted positive pairs 
by Chi-square statistics with FDR as statistically significant associations were utilized for 
the analysis.  
 
Table 6-1: SIDER2 and a Reference Set are used to construct the dataset for the 
experiment 
Group Drugs ADRs True 
Pairs 
False 
Pairs 
Total 
Pairs 
Statistically 
significant 
associations 
True 
positives in 
statistically 
significant 
associations 
SIDER2 811 1879 260,555 395,468 436,865 260,555 28,114 
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Group Drugs ADRs True 
Pairs 
False 
Pairs 
Total 
Pairs 
Statistically 
significant 
associations 
True 
positives in 
statistically 
significant 
associations 
Reference 
Set 
773 1374 40,838 315,544 356,382 215,024 27,765 
 
6.2.3 Performance metrics 
Average precision (AP) is the average of the precision that is measured at the rank at which 
each correct prediction is retrieved. Precision at 100 (Manning et al., 2008) is the precision 
at the first 100 retrieved results. A true positive drug/ADR association, defined as 
“rediscovery”, is an adverse effect that is confirmed by SDIER2 or the reference set. The 
median rank of rediscoveries across statistically significant drug/ADR associations 
approximates the point in the ranked list that half of the known adverse effects were 
recovered by Chi-square statistics with FDR or PSI-double+triple model.  
AP, precision at 100, and median rank of rediscoveries are calculated and compared 
between pre- and post- reranking for the two datasets. A two-sample Kolmogorov-Smirnov 
test was conducted to evaluate if there is a significant difference for the total number of 
rediscoveries at each rank between pre- and post-reranking signals. The rediscovery at each 
rank is also plotted for different dataset.  
To measure the performance with respect to the true positive rate (TPR) and false positive 
rate (FPR), receiver operating characteristic (ROC) curve was plotted for statistically 
significant drug/ADR associations. Subsequently, an area under the ROC curve (AUROC) 
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from the ranking of each model and an area for precision and recall (AUC for Precision-
Recall) were calculated using AUCCalculator (Davis & Goadrich, 2006). 
 
 
6.3 Results 
6.3.1 Performance 
Results of comparing pre-reranking and post-reranking for different datasets are shown in 
Table 6-2. PSI-based models perform better than RRI-based models and both models 
perform better than the random baseline. 
 
Table 6-2: Results of precision and rank-based measures for different groups and 
different datasets 
Test Set Group MAP Precision 
at 100 
Median 
Rank 
AUC for 
Precision-
Recall 
AUROC 
SIDER2 Pre-
reranking 
(Chi) 
0.1424 0.16 103,528 0.1411 0.5708 
Post-
reranking 
(Similarity) 
0.1640 0.21 85,166 0.1639 0.6323 
Reference 
Set 
Pre-
reranking 
(Chi) 
0.1655 0.19 87,218 0.1641 0.5664 
Post-
reranking 
(Similarity) 
0.1847 0.21 75,197 0.1846 0.6173 
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With the SIDER2 dataset, the median rank of true positives with EHR data (pre-reranking 
signals) is 103,528; and in combination with the LBD model (post-reranking signals) it is 
85,166. With the reference set, the median rank of true positives in pre- and post-reranking 
signals is 87,218 and 75,197, respectively. Two-sample Kolmogorov-Smirnov test shows 
there is a significant difference of the accumulated number of true positives at each rank 
(Figure 6-2) between pre- and post- reranking methods for both datasets (all P-value < 
2.2e-16).  
 
 
Figure 6-2: Comparing accumulated number of true positives for each ranking between 
pre- and post-reranking signals for SIDER2 set (top) and the Reference set (bottom) 
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6.3.2 AUC 
Figures 6-3 and 6-4 present the global ROC curves. ROC curve shows the tradeoff between 
sensitivity and specificity. The AUC provides a cumulative estimate of accuracy, and is 
shown for each model in Table 6-2. With respective dataset, AUROC of post-reranking 
method is greater than the pre-reranking method.  
 
 
Figure 6-3: ROC plot of true positive rate and false positive rate for pre- and post-
reranking groups for SIDER2 set 
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Figure 6-4: ROC plot of true positive rate and false positive rate for pre- and post-
reranking groups for the Reference set  
 
6.4 Discussion 
In this experiment, drug/ADR signals that were predicted from EHR data using the best 
performing statistical algorithm were reranked using the PSI model. This resulted in 
significant increases of the true positive rate at a corresponding rank (in comparison to the 
true positive rate with no reranking). Precision and AUC are better performed with post-
reranking method. The experiment demonstrates that the PSI model can filter noisy signals 
using a measure of the plausibility of the relationship between the drugs and ADRs 
concerned.  
Overall, based on what I have learned from the series of experiments, I want to propose the 
architecture for a plausibility-based pharmacovigilance system (Figure 6-5). This 
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framework describes the essential steps: (1) Process EHR data to extract coded drugs and 
possible problems; a NLP tool is required for processing unstructured clinical notes. (2) 
Select a cohort for drug/ADR analysis. (3) From the drug/problem candidates, existing 
known relationships knowledge is used to filter the known drug/problem relationships. (4) 
Conducting statistical analysis for drug/problem candidates and identifying statistically 
significant drug/ADR associations. (5) Using the PSI model to justify plausible drug/ADR 
associations and filtering the statistically detected signals using their plausibility. (6) 
Present plausible drug/ADR signals and their evidence retrieved by the PSI model to 
clinicians or practitioners for review. (7) Automatically submit the detected drug/ADR 
signals with all related clinical information to PV health administrative departments. This 
helps clinicians in making clinical decision for the patients that are taking the relevant 
drugs.  
 
6.5 Conclusion 
This experiment supports my overall hypothesis that the precision of signal detection 
from EHR data can be improved by integrating knowledge from the biomedical literature.  
 
 
  
Figure 6-5: The proposed architecture for a plausibility-based pharmacovigilance system 
1
2
2
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Chapter 7: Key Findings, Innovation, Contributions, Future work and Conclusions 
7.1 Overview and summary of key findings 
For this thesis I conducted four experiments. First, of all the SIDER2 ADRs that occur in an 
outpatient EHR system, I was able to detect 10-15% in that EHR data by using existing 
disproportionality measures and Chi-square statistics with FDR. The Chi-square statistics with 
FDR was demonstrated as the best performing model with an F-measure of 0.1826, evaluated 
against SIDER2. Second, I built two LBD models based on scalable methods of distributional 
semantics (RRI and PSI discovery patterns) to identify possible drug/ADR associations utilizing 
the biomedical literature. The PSI discovery patterns model outperforms the RRI co-occurrence 
based model and can be used to evaluate the plausibility of drug/ADR associations. It has the 
additional advantage of modeling the relations between the involved medical concepts. Third, as 
a consequence of possible false associations that exist in the SIDER side effects dataset used for 
evaluation, I constructed a drug/ADR reference set. This reference set is based on the consistency 
between FAERS and the SIDER data set. I then used this as an additional reference set for 
evaluating side effects. Fourth and last, I applied a plausibility measure obtained through PSI 
discovery patterns to rerank the statistically significant drug/ADR associations detected in EHR 
data, which improved the precision against SIDER2 and the newly developed reference set. This 
verified my overall hypothesis that using literature to justify plausibility can improve the quality 
of signal detection from EHR data.  
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7.2 Innovation 
I have developed means to partially automate the signal evaluation process by integrating 
knowledge extracted from the biomedical literature with possible drug/ADR signals derived from 
EHR data using statistical methods. To do so, recent LBD methods using “discovery patterns” 
were adapted to the task of evaluating the plausibility of drug/ADR signals at scale. To the best of 
my knowledge, this is the first time knowledge from the biomedical literature has been integrated 
with EHR data for signal detection. Previous attempts at applying methods of literature based 
discovery to find possible mechanisms to explain drug/ADR associations were conducted using 
manually defined discovery patterns. My research describes a method to automatically define 
pharmacovigilance related discovery patterns from the literature, and applies those to find 
predication-based explanations in an automated way on a large scale.  
In summary, this research is the first to integrate semantic predications into the signal detection 
process to provide evidence supporting the plausibility of the connection between drugs and 
ADRs. The automated evaluation of plausibility to support causality according to the meaning 
defined by the Bradford-Hill criteria, is a novel contribution to the field of pharmacovigilance and 
to signal detection in general.  
 
7.3 Theoretical contribution 
From a theoretical perspective, my work is motivated by the notion of abductive reasoning as 
described by American philosopher CS Peirce (Peirce, 1955). According to Peirce, abductive 
reasoning (Schvaneveldt & Cohen, 2010) is the process of seeking the best possible explanation 
for an observation. The observation is a given and it is the goal to find an explanation that is 
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sufficient to justify the presence of the observation. This is in contrary to deductive reasoning 
where from a given starting condition possible consequences are deduced. It is also important to 
note the difference between a sufficient and a necessary condition. A sufficient explanation serves 
to explain an observation but its presence is not necessary. Thus, the observation can still be 
explained by other conditions and one explanation does not explicitly exclude others. 
Currently in PV, signals indicating possible causal associations are discovered within a large 
database and then manually evaluated. A problem with this approach is that mined associations 
can be relevant or irrelevant, or may even be negative associations. Exhaustive manual review of 
these potential signals is not feasible. In my research I abduce explanations in an automated way, 
or, in other words, propose and find logical explanations for the identified associations in an 
automated way. The theoretical value added is then to use the generated explanations to 
collectively assess a measure for the plausibility of an association. The theoretical contribution is 
constituted by not primarily focusing on finding explanatory hypotheses but by focusing on 
assessing the plausibility of an observation. Where abductive reasoning is concerned with finding 
truthful explanations for an observation, my framework adds to that by going a step further and 
also assessing the truthfulness of the observation itself. 
 
7.4 Practical contribution 
Practically, the detection of signals from EHR data has the potential to improve post-marketing 
drug surveillance in real world applications. The computational requirements of the employed 
algorithms and tools are sufficiently low to allow for delivery of results in real time. In this context, 
“real time” effectively means timely surveillance, and thus the early detection of ADRs that are 
potentially harmful to patients. In the concluding experiment I showed that augmenting statistical 
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associations with a plausibility measure enhances the identification of known ADRs, suggesting 
that this approach would also lead to more accurate identification of novel ADRs. Furthermore, 
delivery of the underlying explanatory hypotheses to domain experts has the potential to increase 
the efficiency of the critical clinical review process. This is because the number of associations 
that is mined from EHR data is very high, and these signals still have to be manually evaluated. 
Prioritizing signals automatically has the potential to speed up the review process. Noise can be 
separated from those signals supported by plausible evidence because of the evidence provided to 
researchers or practitioners. Moreover, the evidence provided is in a very concise format (at the 
predication level rather than the document level) that allows for the exploration of a large amount 
of evidence in an efficient manner.  
With respect to informatics in general, the methods and procedures of integrating formal 
knowledge can be generalized and applied to other domains. With the rapid growth of use of EHR 
data for clinical research (Hripcsak & Albers, 2013), new findings can be learned from the EHR 
data. The PSI discovery patterns model can be adapted and used to provide the automated 
interpretation of the findings. A very interesting example is outbreak surveillance, for which a 
timely identification of plausible signals is essential. For example, an influenza outbreak can be 
identified from EHR data by mining abnormal lab results, symptoms and outpatient diagnoses. PSI 
discovery patterns can retrieve possible sources, mode of transmission and risk factors (CDC, 
2006) by analyzing the plausible pathways between the virus and the disease/symptoms. This can 
assist field investigators’ work.  
In summary, the detection of signals from EHR data and the subsequent evaluation using 
supporting evidence from literature with PSI discovery patterns in pharmacovigilance on a large 
scale in an automated way has not been done before and has shown good results. The methods and 
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procedures proposed and examined in this work are novel to the field of pharmacovigilance and 
applicable to other informatics areas.   
 
7.5 Future work 
In future work, I plan to improve my methods for the estimation of plausibility, and provide better 
ways for domain experts to explore the evidence that supports the explanatory hypotheses the 
methods generate. Although predications are a concise way to present supporting evidence 
gathered by PSI discovery patterns from the medical literature, the presentation to domain experts 
for review in a concise way still presents a challenge. Since evidence is retrieved based on 
predications which can naturally be built into a graph network, it is straightforward to examine if 
graph algorithms can be utilized to analyze the evidence network. This can result in prioritization 
or the identification of important biological factors, or even biological pathways. Subsequently, 
improved visualizations could highlight specific aspects like biological factors and pathways and 
could put an emphasis on important concepts through their connectedness for example.  This would 
add to the efficacy of the manual review process. 
The methods developed for my research have the potential to support a real-time PV system. This 
work has demonstrated that signal detection and signal evaluation can be done in a partially 
automated and therefore, potentially more timely manner. I will continue working in this direction 
with the aim to contribute to the development of an active drug surveillance system. 
 
7.6 Conclusions 
This thesis demonstrates that drug/ADR associations can be detected from unstructured outpatient 
clinical notes by using statistical mining algorithms. PSI discovery patterns can further improve 
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the precision of detected signals by leveraging knowledge from literature and modeling the 
plausibility of the identified associations. Consequently this work has extended the state of the art 
in EHR-based pharmacovigilance and contributed new ideas that pave the way for further studies 
with the potential to further enhance the field of pharmacovigilance and drug safety.  
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